M

11-31-00

PTO/SB/05 (08-00)

		10	
Name to the control of the control o			

Approved for use through 10/31/2002, OMB 0651-0032 Please type a plus sign (+) inside this box ______ K__ U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. UTILITY 47675-14 Attorney Docket No. Markl, Isabel et al. PATENT APPLICATION First Inventor TRANSMITTAL METHYLATION ALTERED DNA SEQUENCE Title EL695285386US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing Computer Program (Appendix) Applicant claims small entity status. 2. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) opecification [Total Pages 14] [Pages 14] Specification a. X Computer Readable Form (CRF) - Descriptive title of the invention b. Specification Sequence Listing on: Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D i. ☐ CD-ROM or CD-R (2 copies); or - Reference to sequence listing, a table, ii.□ paper or a computer program listing appendix c. Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description 9. Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets 1 Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages [] Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 17 completed) Preliminary Amendment 13. Return Receipt Postcard (MPEP 503) 14. X (Should be specifically itemized) **DELETION OF INVENTOR(S)** Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 16. 1 63(d)(2) and 1.33(b). Application Data Sheet. See 37 CFR 1.76 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional of pnor application No..... Continuation-in-part (CIP) Prior application information: Group / Art Unit: For CONTINUATION OR DIVISIONAL / nm which an oath or declaration is supplied under Box 5b, is considered a part of the diilication and is hereby incorporated by reference. The incorporation can only be relied : submitted application parts. 23504 Customer Number or Bar Code Label Correspondence address below PATENENT & TRADMARK OFFICE Name Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Address Seattle WA City 98101-1688 State Zip Code US Country Telephone 206-622-3150 2066287699 Barry L. Davison Name (Print/Type) P47,309 Registration No. (Attorney/Agent) Signature Date 10-27-2600

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

the state of the s

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Markl, Isabel et al.

Filing Date: October 27, 2000

Serial No.: to be assigned

For: METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED

WITH HUMAN CANCER

Docket: 47675-15

Date: October 27, 2000

Assistant Commissioner for Patents Box Patent Application Washington, DC 20231

STATEMENT UNDER 37 C.F.R. §1.821

Sir:

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821, are the same.

Respectfully submitted,

Barry L. Davison

Attorney for Applicants Registration No. P47,309

Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688

Tel: 206-628-7621 Fax: 206-628-7699

15

20

25

30

35

METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER

5 Technical Field of the Invention

The present invention relates to novel human DNA sequences that exhibit altered methylation patterns (hypermethylation or hypomethylation) in cancer patients. These novel methylation-altered DNA sequences are useful as diagnostic, prognostic and therapeutic markers for human cancer.

Background of the Invention

The identification of early genetic changes in tumorigenesis is a primary focus in molecular cancer research. Characterization of the nature and pattern of cancer-associated genetic alterations will allow for early detection, diagnosis and treatment of cancer. Such genetic alterations in vertebrates fall generally into one of three categories: gain or loss of genetic material; mutation of genetic material; or methylation at cytosine residues in CpG dinucleotides within "CpG islands." Among these, DNA methylation is uniquely reversible, and changes in methylation state are known to affect gene expression (e.g., transcriptional initiation of genes where CpG islands located at or near the promoter region) or genomic stability.

Methylation of CpG dinucleotides within CpG islands. DNA, in higher order eukaryotic organisms, is methylated only at cytosine residues located 5' to guanosine residues in CpG dinucleotides. This covalent modification of the C-5 position of the cytosine base by the enzyme DNA (cytosine-5)-methyltransferase results in the formation of 5-methylcytosine (5-mCyt), and gives this base unique properties (e.g., susceptibility to undergo spontaneous deamination). This enzymatic conversion is the only epigenetic modification of DNA known to exist in vertebrates, and is essential for normal embryonic development (Bird, A.P., Cell 70:5-8, 1992; Laird & Jaenisch, Human Molecular Genetics 3:1487-1495, 1994; Li et al., Cell 69:915-926, 1992).

The presence of 5-mCyt at CpG dinucleotides has resulted in the 5-fold depletion of this sequence in the genome during the course of vertebrate evolution (Schroderet & Gartler, *Proc. Nat. Acad. Sci. USA* 89:957-961, 1992), presumably due to spontaneous deamination of 5-mCyt to Thymidine. Certain areas of the genome, however, do not show such depletion, and are referred to as "CpG islands" (Bird, A.P., *Nature* 321:209-213, 1986; Gardiner-Garden & Frommer, *J. Mol. Biol.* 196:261-282, 1987). These CpG islands comprise only approximately 1% of the vertebrate genome, yet account for about 15% of the total number of genomic CpG dinucleotides (Antequera & Bird, *Proc. Nat. Acad. Sci. USA* 90:11995-11999, 1993). CpG islands contain the expected (*i.e.*, the non-evolutionarily depleted) frequency of

F:\DOCS\47675\14\ORCA-14-final.doc Seattle

10

15

20

25

30

35

CpGs (with an Observed/Expected Ratio¹ >0.6), are GC-rich (with a GC Content² >0.5) and are typically between about 0.2 to about 1 kb in length.

Methylation within CpG islands affects gene expression. CpG islands are located upstream of many housekeeping and tissue-specific genes, but may also extend into gene coding regions (Cross & Bird, Current Opinions in Genetics and Development 5:309-314, 1995; Larsen et al., Genomics 13:1095-1107, 1992). The methylation of cytosines within CpG islands in somatic tissues is believed to affect gene expression. Methylation has been inversely correlated with gene activity and may lead to decreased gene expression by a variety of mechanisms including inhibition of transcription initiation (Bird, A.P., Nature 321:209-213, 1986; Delgado et al., EMBO Journal 17:2426-2435, 1998), disruption of local chromatin structure (Counts & Goodman, Molecular Carcinogenesis 11:185-188, 1994; Antequera et al., Cell 62:503-514, 1990), and recruitment of proteins that interact specifically with methylated sequences and thereby directly or indirectly prevent transcription factor binding (Bird, A.P., Cell 70:5-8, 1992; Counts & Goodman, Molecular Carcinogenesis 11:185-188, 1994; Cedar, H., Cell 53:3-4, 1988). Many studies have demonstrated the effect of methylation of CpG islands on gene expression (e.g., the CDKN2A/p16 gene; Gonzalez-Zulueta et al., Cancer Research 55:4531-4535, 1995), but most CpG islands on autosomal genes remain unmethylated in the germline, and methylation of these islands is usually independent of gene expression. Tissue-specific genes are typically unmethylated in the respective target organs but are methylated in the germline and in non-expressing adult tissues, while CpG islands of constitutively expressed housekeeping genes are normally unmethylated in the germline and in somatic tissues.

Methylation within CpG islands affects the expression of genes involved in cancer. Data from a group of studies show the presence of altered methylation in cancer cells relative to non-cancerous cells. These studies show not only alteration of the overall genomic levels of DNA methylation, but also changes in the distribution of methyl groups. For example, abnormal methylation of CpG islands that are associated with tumor suppressor genes or oncogenes within a cell may cause altered gene expression. Such altered gene expression may provide a population of cells with a selective growth advantage and thereby result in selection of these cells to the detriment of the organism (i.e., cancer).

Insufficient correlative data. Unfortunately, the mere knowledge of the basic existence of altered methylation of CpG dinucleotides within CpG islands of cancer cells relative to normal cells, or of the fact that in particular instances such methylation changes result in altered gene expression (or chromatin structure or stability), is inadequate to allow for effective diagnostic, prognostic and therapeutic application of this knowledge. This is

¹ Calculated as: [number of CpG sites / (number of C bases X number of G bases)] X band length for each fragment.

² Calculated as: (number of C bases + number of G bases) / band length for each fragment.

10

15

20

25

30

35

because only a limited number of CpG islands have been characterized, and thus there is insufficient knowledge, as to which particular CpG islands, among many, are actually involved in, or show significant correlation with cancer or the etiology thereof. Moreover, complex methylation patterns, involving a plurality of methylation-altered DNA sequences, including those that may have the sequence composition to qualify as CpG islands, may exist in particular cancers.

Therefore there is a need in the art to identify and characterize specific methylation altered DNA sequences, and to correlate them with cancer to allow for their diagnostic, prognostic and therapeutic application.

Summary of the Invention

The present invention provides for a diagnostic or prognostic assay for cancer, comprising: obtaining a tissue sample from a test tissue; performing a methylation assay on DNA derived from the tissue sample, wherein the methylation assay determines the methylation state of a CpG dinucleotide within a DNA sequence of the DNA, and wherein the DNA sequence is a sequence selected from the group consisting of sequences of SEQ ID NOS:1-103, sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103, and combinations thereof, wherein the CpG island sequence associated with the sequence of the particular SEO ID NO is that contiguous sequence of genomic DNA that encompasses at least one nucleotide of the particular SEQ ID NO sequence, and satisfies the criteria of having both a frequency of CpG dinucleotides corresponding to an Observed/Expected Ratio >0.6, and a GC Content >0.5; and determining a diagnosis or prognosis based, at least in part, upon the methylation state of the CpG dinucleotide within the DNA sequence. Preferably, the DNA sequence is a sequence selected from the group consisting of CpG island sequences associated with sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103, and combinations thereof. Preferably, the DNA sequence is a sequence selected from the group consisting of CpG island sequences associated with sequences of SEQ ID NOS: 2, 4, 6, 7, 9-16, 19, 20, 22-33, 35-43, 48, 51-55, 59, 60, 64, 71, 76, 78-81, 84 and 87-90, and combinations thereof. Preferably, the methylation assay procedure is selected from the group consisting of MethyLight, MS-SnuPE (methylation-sensitive single nucleotide primer extension), MSP (methylation-specific PCR), MCA (methylated CpG island amplification), COBRA (combined bisulfite restriction analysis), and combinations thereof. Preferably, the methylation state of the CpG dinucleotide within the DNA sequence is that of hypermethylation, hypomethylation or normal methylation. Preferably, the cancer is selected

10

15

20

25

35

from the group consisting of bladder cancer, prostate cancer, colon cancer, lung cancer, renal cancer, leukemia, breast cancer, uterine cancer, astrocytoma, glioblastoma, and neuroblastoma. Preferably, the cancer is bladder cancer, or prostate cancer.

The present invention further provides a kit useful for the detection of a methylated CpG-containing nucleic acid comprising a carrier means containing one or more containers comprising: a container containing a probe or primer which hybridizes to any region of a sequence selected from the group consisting of SEQ ID NOS:1-103, and sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103; and additional standard methylation assay reagents required to affect detection of methylated CpG-containing nucleic acid based on the probe or primer. Preferably, the additional standard methylation assay reagents are standard reagents for performing a methylation assay from the group consisting of MethyLight, MS-SNuPE, MSP, MCA, COBRA, and combinations thereof. Preferably, the probe or primer comprises at least about 12 to 15 nucleotides of a sequence selected from the group consisting of SEQ ID NOS:1-103, and sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103.

The present invention further provides an isolated nucleic acid molecule comprising a methylated or unmethylated polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:97, and SEQ ID NO:100. Preferably the nucleic acid is methylated. Preferably, the nucleic acid is unmethylated.

Detailed Description of the Invention

30 Definitions:

"GC Content" refers, within a particular DNA sequence, to the [(number of C bases + number of G bases) / band length for each fragment].

"Observed/Expected Ratio" ("O/E Ratio") refers to the frequency of CpG dinucleotides within a particular DNA sequence, and corresponds to the [number of CpG sites / (number of C bases X number of G bases)] X band length for each fragment.

"CpG Island" refers to a contiguous region of genomic DNA that satisfies the criteria of (1) having a frequency of CpG dinucleotides corresponding to an "Observed/Expected Ratio" >0.6), and (2) having a "GC Content" >0.5. CpG islands are

10

15

20

25

30

typically, but not always, between about 0.2 to about 1 kb in length. A CpG island sequence associated with a particular SEQ ID NO sequence of the present invention is that contiguous sequence of genomic DNA that encompasses at least one nucleotide of the particular SEQ ID NO sequence, and satisfies the criteria of having both a frequency of CpG dinucleotides corresponding to an Observed/Expected Ratio >0.6), and a GC Content >0.5.

"Methylation state" refers to the presence or absence of 5-methylcytosine ("5-mCyt") at one or a plurality of CpG dinucleotides within a DNA sequence.

"Hypermethylation" refers to the methylation state corresponding to an *increased* presence of 5-mCyt at one or a plurality of CpG dinucleotides within a DNA sequence of a test DNA sample, relative to the amount of 5-mCyt found at corresponding CpG dinucleotides within a normal control DNA sample.

"Hypomethylation" refers to the methylation state corresponding to a *decreased* presence of 5-mCyt at one or a plurality of CpG dinucleotides within a DNA sequence of a test DNA sample, relative to the amount of 5-mCyt found at corresponding CpG dinucleotides within a normal control DNA sample.

"Methylation assay" refers to any assay for determining the methylation state of a CpG dinucleotide within a sequence of DNA.

"MS.AP-PCR" (Methylation-Sensitive Arbitrarily-Primed Polymerase Chain Reaction) refers to the art-recognized technology that allows for a global scan of the genome using CG-rich primers to focus on the regions most likely to contain CpG dinucleotides, and described by Gonzalgo et al., *Cancer Research* 57:594-599, 1997.

"MethyLight" refers to the art-recognized fluorescence-based real-time PCR technique described by Eads et al., Cancer Res. 59:2302-2306, 1999.

"Ms-SNuPE" (Methylation-sensitive Single Nucleotide Primer Extension) refers to the art-recognized assay described by Gonzalgo & Jones, *Nucleic Acids Res.* 25:2529-2531, 1997.

"MSP" (Methylation-specific PCR) refers to the art-recognized methylation assay described by Herman et al. *Proc. Natl. Acad. Sci. USA* 93:9821-9826, 1996, and by US Patent No. 5,786,146.

"COBRA" (Combined Bisulfite Restriction Analysis) refers to the art-recognized methylation assay described by Xiong & Laird, *Nucleic Acids Res.* 25:2532-2534, 1997.

"MCA" (Methylated CpG Island Amplification) refers to the methylation assay described by Toyota et al., *Cancer Res.* 59:2307-12, 1999, and in WO 00/26401A1.

35 Overview

The present invention provides for 103 DNA sequences (*i.e.*, "marker sequences") having distinct methylation patterns in cancer, as compared to normal tissue. These methylation-altered DNA sequence embodiments correspond to 103 DNA fragments isolated

10

15

20

30

35

from bladder and prostate cancer patients, and in many instances, represent novel sequences not found in the GenBank database. None of the instant sequence embodiments have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to, those of the bladder and prostate. The significance of such methylation patterns lies in the value of altered fragments as potential prognostic, diagnostic and therapeutic markers in the treatment of human cancers.

Identification of Methylation-altered Marker Sequences in Genomic DNA

The MS.AP-PCR technique was used to scan the genomes of bladder or prostate cancer patients for DNA methylation changes relative to normal individuals, because the pattern is known to be highly conserved. A total of 103 DNA sequence embodiments (methylation-altered DNA sequences; "marker sequences") were isolated and characterized as having distinct methylation patterns in cancer, as compared to normal tissue.

Methods for the Identification of Marker Sequences in Genomic DNA. There are a variety of art-recognized genome scanning methods that have been used to identify altered methylation sites in cancer cells. For example, one method involves restriction landmark genomic scanning (Kawai et al., Mol. Cell. Biol. 14:7421-7427, 1994), another involves MCA (methylated CpG island amplification; Toyota et al., Cancer Res. 59:2307-12, 1999), and yet another involves MS.AP-PCR (Methylation-Sensitive Arbitrarily-Primed Polymerase Chain Reaction; Gonzalgo et al., Cancer Res. 57:594-599, 1997), which allows for a global scan of the genome using CG-rich primers to focus on the regions most likely to contain CpG dinucleotides. The MS.AP-PCR technique used in the present invention is a rapid and efficient method to screen ("scan") for altered methylation patterns in genomic DNA and to isolate specific sequences associated with these changes.

Briefly, genomic DNA from the tissue of bladder or prostate cancer patients was prepared using standard, art-recognized methods. Restriction enzymes (e.g., HpaII) with different sensitivities to cytosine methylation in their recognition sites were used to digest these genomic DNAs prior to arbitrarily primed PCR amplification with GC-rich primers. Fragments that showed differential methylation (e.g., hypermethylation or hypomethylation, based on the methylation sensitivity of the restriction enzyme, or upon DNA sequence analysis or Ms-SNuPE analysis; Gonzalgo & Jones, Nucleic Acids Res 25:2529-2531, 1997) were cloned and sequenced after resolving the PCR products on high-resolution polyacrylamide gels. The cloned fragments were used as probes for Southern blot analysis to confirm differential methylation of these regions in the tissue. Methods for DNA cloning, sequencing, PCR, high-resolution polyacrylamide gel resolution and Southern blot analysis are well known by those of ordinary skill in the relevant art.

Results. A total of 500 DNA fragments that underwent either hypermethylation (an increase in the level of methylation relative to normal) or hypomethylation (a decrease in the

10

15

20

25

30

level of methylation relative to normal) were isolated from the scanned patients genomic DNA. A total of 178 of these fragments were sequenced, of which 103 were *novel* in that they corresponded to DNA loci whose methylation pattern had not previously been characterized. The corresponding sequences are disclosed as [SEQ ID NOS:1-103], wherein for certain sequences, the letter "n" refers to an undetermined nucleotide base.

Novel marker sequences identified by MS.AP-PCR. Table I shows an overall summary of methylation patterns and sequence data corresponding to the 103 DNA fragments identified by MS.AP-PCR. A total of 103 fragments were sequenced following identification as becoming either hypermethylated (gain of methylation; noted as having a hypermethylation pattern) or hypomethylated (loss of methylation; noted as having a hypomethylation pattern) relative to normal tissue. For the fragments of each category, the "Average GC Content" is shown, calculated as (number of C bases + number of G bases)/band length for each fragment, as well as the average Observed/Expected Ratio ("O/E Ratio"), calculated as [number of CpG sites/(number of C bases X number of G bases)] X band length for each fragment. Additionally, the percent of fragments that qualify as CpG islands is listed, and corresponds to the percentage of all fragments within each category that have sequence compositions that satisfy the criteria of having a "GC Content" >0.5 and an "O/E Ratio" >0.6.

Thus, of these 103 fragments identified by MS.AP-PCR, 60 showed hypermethylation (Table I, upper row; Table II, [SEQ ID NOS:1-60]) while 43 showed hypomethylation (Table I, lower row; Table II, [SEQ ID NOS:61-103]). Moreover, 55 (43 hypermethylated, and 12 hypomethylated) of the 103 fragments correspond to CpG islands (*i.e.*, fulfill the criteria of a GC content >0.5 and an Observed/Expected Ratio >0.6;), whereas the other 48 (17 hypermethylated and 31 hypomethylated) fragments do not meet the criteria for CpG islands (*see* Table II).

TABLE I. Summary of 103 DNA Fragments Identified by MS.AP-PCR

DNA Fragment Type	Methylation Pattern (relative to normal)	Number of Fragments (103 total)	Average GC Content	Average O/E Ratio	Percent that correspond to CpG Islands
Hypermethylated Fragments	Hyper- methylation	60	0.54	0.72	72%
Hypomethylated Fragments	Hypo-methylation	43	0.52	0.48	28%

Table II shows a summary of methylation pattern and sequence data for each *individual* sequence embodiment ([SEQ ID NOS:1-103]), corresponding to the 103 DNA fragments identified by MS.AP-PCR. Data for the 103 fragments was divided into either hypermethylated ([SEQ ID NOS:1-60]) or hypomethylated ([SEQ ID NOS:61-103]) categories. Table II also lists, for each sequence embodiment, the corresponding "Fragment

10

15

20

Name," fragment "Size" (in base pairs; "bp"), "GC Content," Observed/Expected Ratio ("O/E Ratio"), "Description" (i.e., as a CpG island if criteria are met), "Inventor Initials" (IDCM = Isabel D.C. Markl, JC = Jonathan Cheng, GL = Gangning Liang, HF = Hualin Fu, YT = Yoshitaka Tomigahara), "Cancer Source," and "Chromosome Match" to the GenBank database. A dash ("-") indicates that no GenBank chromosome match existed, or that only a low-scoring partial match was found. Averages of the "GC Content" and "O/E Ratio," along with the percent of fragments that are CpG islands, are listed after the last member of both the hypermethylated and hypomethylated categories.

Therefore, the present invention provides for 103 DNA fragments and corresponding marker sequence embodiments (*i.e.*, methylation-altered DNA sequences) that are useful in cancer prognostic, diagnostic and therapeutic applications.

Additionally, at least 55 of these 103 sequences correspond to CpG islands (based on GC Content and O/E ration); namely [SEQ ID NOS:2, 4, 6, 7, 9-16, 19, 20, 22-33, 35-43, 48, 51-55, 59, 60, 64, 71, 76, 78-81, 84 and 87-90]. Thus, based on the fact that the methylation state of a portion of a given CpG island is generally representative of the island as a whole, the present invention further encompassed the novel use of the 55 CpG islands associated with [SEQ ID NOS:2, 4, 6, 7, 9-16, 19, 20, 22-33, 35-43, 48, 51-55, 59, 60, 64, 71, 76, 78-81, 84 and 87-90] in cancer prognostic, diagnostic and therapeutic applications, where a CpG island sequence associated with the sequence of a particular SEQ ID NO is that contiguous sequence of genomic DNA that encompasses at least one nucleotide of the particular SEQ ID NO sequence, and satisfies the criteria of having both a frequency of CpG dinucleotides corresponding to an Observed/Expected Ratio >0.6, and a GC Content >0.5.

TABLE II. Summary of MS.AP-PCR Fragments Sequenced

Methylation	Fragment	Size	GC	O/E	Description	Inventor	Cancer	Chromosome	SEQ
Pattern	Name	(bp)	Content	Ratio	-	Initials	Source	Matches	ID NO]
Hyper-									
methylation		1	j						
category	11-1A	510	0.44	0.74		IDCM	Bladder	-	1
	14-3B	313	0.58	0.74	CpG Island	IDCM	Bladder	2	2
	18-2B	165	0.57	0.45		IDCM	Bladder	7	3
	24-1B	601	0.51	0.72	CpG Island	IDCM	Bladder	Xp11	4
	26-1B	801	0.48	0.56		IDCM	Bladder	-	5
	26-2C	204	0.50	0.63	CpG Island	IDCM	Bladder	_	6
	30-3D	205	0.55	1.25	CpG Island	IDCM	Bladder	14	7
	32-3E	597	0.57	0.10	_	IDCM	Bladder	20q12-13.1	8
	34-2B	500	0.62	0.66	CpG Island	IDCM	Bladder	20	9
	34-4B	343	0.70	0.81	CpG Island	IDCM	Bladder	-)	10
	34-5D	291	0.62	0.96	CpG Island	IDCM	Bladder	9	11
į	34-6A	266	0.64	0.93	CpG Island	IDCM	Bladder	-	12
	35-1C	553	0.64	0.63	CpG Island	IDCM	Bladder	-	13
	36-2D	156	0.60	0.58	CpG Island	IDCM	Bladder	10	14
Ì	38-1A	300	0.70	0.80	CpG Island	IDCM	Bladder	10	15
ļ	38-2B	196	0.56	0.89	CpG Island	IDCM	Bladder	15	16
l	7-8E	299	0.59	0.39	-	IDCM	Bladder	17q21-22	17
	83-4B	363	0.54	0.49		IDCM	Bladder	-	18

Methylation	Fragment	Size	GC	O/E	Description	Inventor	Cancer	Chromosome	SEQ
Pattern	Name	(bp)	Content		•	Initials	Source	Matches	ID NO
!	84-1D	322	0.55	0.90	CpG Island	IDCM	Bladder	7	19
,	101-3E	255	0.57	0.83	CpG Island	IDCM	Bladder	17	20
į Į	M1-5A	406	0.45	0.96	1	IDCM	Bladder	1	21
	U2-8E	210	0.56	0.61	CpG Island	IDCM	Bladder	2	22
,	U12-1A	310	0.56	0.81	CpG Island	IDCM	Bladder	2	23
ĺ	U7-4A	305	0.59	0.80	CpG Island	IDCM	Bladder	-	24
	NU9-5A	379	0.67	0.83	CpG Island	JC	Bladder	-	25
	3-17-8-B	625	0.48	0.72	CpG Island	GL	Bladder	18	26
	4-10-4-A	499	0.55	0.30	CpG Island	GL	Bladder	7	27
	1-1-1-A	561	0.58	0.98	CpG Island	GL	Bladder	20	28
	3-17-8-A	717	0.50	0.68	CpG Island	GL	Bladder	17	29
	G145-H	280	0.50	1.10	CpG Island	GL	Bladder	11	30
	1-1-1-D	270	0.50	0.60	CpG Island	GL	Bladder	2	31
	1-1-1-C	347	0.65	1.25	CpG Island	GL	Bladder	-	32
	G178-A	342	0.55	0.85	CpG Island	GL	Bladder	2	33
	34-A	370	0.62	0.44	_	HF	Prostate	-	34
	34-D	213	0.53	0.74	CpG Island	HF	Prostate	2	35
	35-D	173	0.56	0.66	CpG Island	HF	Prostate	3	36
	36-A	369	0.67	0.70	CpG Island	HF	Prostate	-	37
	40-A	123	0.60	1.16	CpG Island	HF	Prostate	- i	38
	91-1	450	0.64	0.86	CpG Island	YT	Bladder	5 or 16q24.3	39
	93-2	593	0.51	0.68	CpG Island	YT	Bladder	Xp11	40
	93-3	457	0.52	0.94	CpG Island	YT	Bladder	Xp22.1-22.3	41
	94-8	211	0.66	0.96	CpG Island	YT	Bladder		42
	95-5	141	0.63	0.79	CpG Island	YT	Bladder	14	43
	97-5	559	0.56	0.40	CPG Island	YT	Bladder	,	44
	98-1	433	0.46	0.96		YT	Bladder	1	45
ļ	100-1	487	0.59	0.58		YT	Bladder	14	46
	100-2	403	0.60	0.47		YT	Bladder	3	47
	100-6	155	0.57	0.99	CpG Island	YT	Bladder	20	48
	4-2	256	0.57	0.40	CpG Island	YT	Bladder	7	49
	5-8	224	0.47	0.96		YT	Bladder	5	50
	6-4	313	0.70	0.82	CpG Island	YT	Bladder	-	51
	7-6	385	0.70	0.88	CpG Island	YT	Bladder		52
	13-3	307	0.59	0.89	CpG Island	YT	Bladder	10	53
	15-2	182	0.62	0.92	CpG Island	YT	Bladder	13	54
	23-2		0.54	0.87	CpG Island	YT	Bladder	Xp22.1-22.3	55
	39-2	795	0.46	0.64	opg island	YT	Bladder	13	56
	40-2	438	0.62	0.51		YT	Bladder	10	57
	41-3	611	0.47	0.70		YT	Bladder	18	58
	105-4	291	0.58	0.71	CpG Island	YT	Bladder	5	59
	107-8	226	0.53	0.96	CpG Island	YT	Bladder	11	60
					· ·				-
AVERAGE			0.54	0.72	72% islands				
Hypo-									
methylation	14.30	500	0.55	0.51		DC1	D1. 11		
category	14-2B	580	0.55	0.51		IDCM	Bladder	2	61
	16-1B	633	0.56	0.39		IDCM	Bladder	17	62
	18-1B	703	0.45	0.35	C. C. T. 1	IDCM	Bladder	17	63
Į.	19-1B	420	0.66	0.87	CpG Island	IDCM	Bladder	-	64
:	20-1B	496	0.61	0.59		IDCM	Bladder	-	65
ĺ	21-2C	637	0.60	0.33		IDCM	Bladder	9q34	66
·	29-1A	595	0.55	0.27		IDCM	Bladder	Xp11.23	67
1	29-2B	580	0.47	0.77		IDCM	Bladder	-	68
}	32-1A	589	0.59	0.48		IDCM	Bladder	-	69
	34-1B	450	0.42	0.46		IDCM	Bladder	- [70
Ì	34-3B	432	0.70	0.61	CpG Island	IDCM	Bladder	-	71

10

Methylation		Size	GC	O/E	Description	Inventor	Cancer		[SEQ
Pattern	Name	(bp)	Content			Initials	Source	Matches	ID NO]
	32-2B	748	0.47	0.24		IDCM	Bladder	2	72
	32-4B	599	0.57	0.15		IDCM	Bladder	20q12-13.1	73
	32-5B	614	0.58	0.20	1	IDCM	Bladder	-	74
	33-1A	552	0.54	0.32	ļ	IDCM	Bladder	10	75
	5-1E	501	0.61	1.04	CpG Island	IDCM	Bladder	-	76
	6-1A	826	0.55	0.36		IDCM	Bladder	22q13.32- 13.33	77
	7-5D	433	0.59	0.85	CpG Island	IDCM	Bladder	5	78
	8-7C	424	0.58	0.83	CpG Island	IDCM	Bladder	5	79
	30-6D	285	0.63	0.72	CpG Island	IDCM	Bladder	1	80
	66-2E	401	0.54	0.82	CpG Island	IDCM	Bladder	16	81
	78-1C	268	0.54	0.41	[-	IDCM	Bladder	_	82
	97-2E	989	0.53	0.16	į	IDCM	Bladder	-	83
	M1-8C	250	0.64	0.99	CpG Island	IDCM	Bladder	-	84
	M2-5A	402	0.50	0.45		IDCM	Bladder	5	85
	M1-4P	595	0.43	0.41	Ì	IDCM	Bladder	-	86
	M12-10A	304	0.53	0.76	CpG Island	IDCM	Bladder	7	87
	M12-12C	296	0.51	0.64	CpG Island	IDCM	Bladder	17	88
	M2-8M	220	0.67	0.62	CpG Island	IDCM	Bladder	6q27	89
	NU4-3A	273	0.63	1.02	CpG Island	JC	Bladder	-	90
	NU5-2A	361	0.44	0.73		JC	Bladder	6q14.3-15	91
	88-5	462	0.62	0.39	j	YT	Bladder		92
i	90-1	591	0.66	0.45		YT	Bladder	19	93
	91-3	279	0.58	0.45		YT	Bladder	5 or 16q24.3	94
i	91-4	351	0.55	0.30	1	YT	Bladder	18 q2 3	95
	91-7	171	0.61	0.59		YT	Bladder	11	96
	89-3	743	0.55	0.43		YT	Bladder	-	97
:	94-2	589	0.53	0.41		YT	Bladder	22q13.31- 13.32	98
i	94-3	538	0.53	0.49		YT	Bladder	5 or 18	99
	94-4	486	0.61	0.57		YT	Bladder	-	100
	94-5	450	0.60	0.45	!	YT	Bladder	1p36.2-36.3	101
	94-6	292	0.58	0.32		YT	Bladder	8 or 9	102
	96-4	395	0.63	0.54		YT	Bladder	9	103
AVERAGE			0.52	0.48	28% islands]			

Diagnostic and Prognostic Assays for Cancer. The present invention provides for diagnostic and prognostic cancer assays based on determination of the methylation state of one or more of the disclosed 103 methylation-altered DNA sequence embodiments. Typically, such assays involve obtaining a tissue sample from a test tissue, performing a methylation assay on DNA derived from the tissue sample, and making a diagnosis or prognosis based thereon.

The methylation assay is used to determine the methylation state of one or a plurality of CpG dinucleotide within a DNA sequence of the DNA sample. According to the present invention, possible methylation states include *hypermethylation* and *hypomethylation*, relative to a normal state (*i.e.*, non-cancerous control state). Hypermethylation and hypomethylation refer to the methylation states corresponding to an *increased* or *decreased*, respectively,

10

15

20

25

30

35

presence 5-methylcytosine ("5-mCyt") at one or a plurality of CpG dinucleotides within a DNA sequence of the test sample, relative to the amount of 5-mCyt found at corresponding CpG dinucleotides within a normal control DNA sample.

A diagnosis or prognosis is based, at least in part, upon the determined methylation state of the sample DNA sequence compared to control data obtained from normal, non-cancerous tissue.

Methylation Assay Procedures. Various methylation assay procedures are known in the art, and can be used in conjunction with the present invention. These assays allow for determination of the methylation state of one or a plurality of CpG dinucleotides (e.g., CpG islands) within a DNA sequence. Such assays involve, among other techniques, DNA sequencing of bisulfite-treated DNA, PCR (for sequence-specific amplification), Southern blot analysis, use of methylation-sensitive restriction enzymes, etc.

For example, genomic sequencing has been simplified for analysis of DNA methylation patterns and 5-methylcytosine distribution by using bisulfite treatment (Frommer et al., *Proc. Natl. Acad. Sci. USA* 89:1827-1831, 1992). Additionally, restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA is used, *e.g.*, the method described by Sadri & Hornsby (*Nucl. Acids Res.* 24:5058-5059, 1996), or COBRA (Combined Bisulfite Restriction Analysis) (Xiong & Laird, *Nucleic Acids Res.* 25:2532-2534, 1997).

COBRA. COBRA analysis is a quantitative methylation assay useful for determining DNA methylation levels at specific gene loci in small amounts of genomic DNA (Xiong & Laird, Nucleic Acids Res. 25:2532-2534, 1997). Briefly, restriction enzyme digestion is used to reveal methylation-dependent sequence differences in PCR products of sodium bisulfitetreated DNA. Methylation-dependent sequence differences are first introduced into the genomic DNA by standard bisulfite treatment according to the procedure described by Frommer et al. (Proc. Natl. Acad. Sci. USA 89:1827-1831, 1992). PCR amplification of the bisulfite converted DNA is then performed using primers specific for the interested CpG islands, followed by restriction endonuclease digestion, gel electrophoresis, and detection using specific, labeled hybridization probes. Methylation levels in the original DNA sample are represented by the relative amounts of digested and undigested PCR product in a linearly quantitative fashion across a wide spectrum of DNA methylation levels. In addition, this technique can be reliably applied to DNA obtained from microdissected paraffin-embedded tissue samples. Typical reagents (e.g., as might be found in a typical COBRA-based kit) for COBRA analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); restriction enzyme and appropriate buffer; gene-hybridization oligo; control hybridization oligo; kinase labeling kit for oligo probe; and radioactive nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery regents or kit (e.g.,

10

15

20

25

30

35

precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components.

Preferably, assays such as "MethyLight" (a fluorescence-based real-time PCR technique) (Eads et al., *Cancer Res.* 59:2302-2306, 1999), Ms-SNuPE (Methylation-sensitive Single Nucleotide Primer Extension) reactions (Gonzalgo & Jones, *Nucleic Acids Res.* 25:2529-2531, 1997), methylation-specific PCR ("MSP"; Herman et al., *Proc. Natl. Acad. Sci. USA* 93:9821-9826, 1996; US Patent No. 5,786,146), and methylated CpG island amplification ("MCA";Toyota et al., *Cancer Res.* 59:2307-12, 1999) are used alone or in combination with other of these methods.

MethyLight. The MethyLight assay is a high-throughput quantitative methylation assay that utilizes fluorescence-based real-time PCR (TaqMan ®) technology that requires no further manipulations after the PCR step (Eads et al., Cancer Res. 59:2302-2306, 1999). Briefly, the MethyLight process begins with a mixed sample of genomic DNA that is converted, in a sodium bisulfite reaction, to a mixed pool of methylation-dependent sequence differences according to standard procedures (the bisulfite process converts unmethylated cytosine residues to uracil). Fluorescence-based PCR is then performed either in an "unbiased" (with primers that do not overlap known CpG methylation sites) PCR reaction, or in a "biased" (with PCR primers that overlap known CpG dinucleotides) reaction. Sequence discrimination can occur either at the level of the amplification process or at the level of the fluorescence detection process, or both.

The MethyLight may assay be used as a quantitative test for methylation patterns in the genomic DNA sample, wherein sequence discrimination occurs at the level of probe hybridization. In this quantitative version, the PCR reaction provides for unbiased amplification in the presence of a fluorescent probe that overlaps a particular putative methylation site. An unbiased control for the amount of input DNA is provided by a reaction in which neither the primers, nor the probe overlie any CpG dinucleotides. Alternatively, a qualitative test for genomic methylation is achieved by probing of the biased PCR pool with either control oligonucleotides that do not "cover" known methylation sites (a fluorescence-based version of the "MSP" technique), or with oligonucleotides covering potential methylation sites.

The MethyLight process can by used with a "TaqMan®" probe in the amplification process. For example, double-stranded genomic DNA is treated with sodium bisulfite and subjected to one of two sets of PCR reactions using TaqMan® probes; e.g., with either biased primers and TaqMan® probe, or unbiased primers and TaqMan® probe. The TaqMan® probe is dual-labeled with fluorescent "reporter" and "quencher" molecules, and is designed to be specific for a relatively high GC content region so that it melts out at about 10 °C higher temperature in the PCR cycle than the forward or reverse primers. This allows the TaqMan® probe to remain fully hybridized during the PCR annealing/extension step. As the

10

15

20

25

30

35

Taq polymerase enzymatically synthesizes a new strand during PCR, it will eventually reach the annealed TaqMan® probe. The Taq polymerase 5' to 3' endonuclease activity will then displace the TaqMan® probe by digesting it to release the fluorescent reporter molecule for quantitative detection of its now unquenched signal using a real-time fluorescent detection system.

Typical reagents (e.g., as might be found in a typical MethyLight-based kit) for MethyLight analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); TaqMan® probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

Ms-SNuPE. The Ms-SNuPE technique is a quantitative method for assessing methylation differences at specific CpG sites based on bisulfite treatment of DNA, followed by single-nucleotide primer extension (Gonzalgo & Jones, Nucleic Acids Res. 25:2529-2531, 1997). Briefly, genomic DNA is reacted with sodium bisulfite to convert unmethylated cytosine to uracil while leaving 5-methylcytosine unchanged. Amplification of the desired target sequence is then performed using PCR primers specific for bisulfite-converted DNA, and the resulting product is isolated and used as a template for methylation analysis at the CpG site(s) of interest. Small amounts of DNA can be analyzed (e.g., microdissected pathology sections), and it avoids utilization of restriction enzymes for determining the methylation status at CpG sites. Typical reagents (e.g., as might be found in a typical Ms-SNuPE-based kit) for Ms-SNuPE analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); optimized PCR buffers and deoxynucleotides; gel extraction kit; positive control primers; Ms-SNuPE primers for specific gene; reaction buffer (for the Ms-SNuPE reaction); and radioactive nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery regents or kit (e.g., precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components.

MSP. MSP (methylation-specific PCR) allows for assessing the methylation status of virtually any group of CpG sites within a CpG island, independent of the use of methylation-sensitive restriction enzymes (Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; US Patent No. 5,786,146). Briefly, DNA is modified by sodium bisulfite converting all unmethylated, but not methylated cytosines to uracil, and subsequently amplified with primers specific for methylated versus unmethylated DNA. MSP requires only small quantities of DNA, is sensitive to 0.1% methylated alleles of a given CpG island locus, and can be performed on DNA extracted from paraffin-embedded samples. Typical reagents (e.g., as might be found in a typical MSP-based kit) for MSP analysis may include, but are not limited to: methylated and unmethylated PCR primers for specific gene (or methylation-altered DNA sequence or CpG island), optimized PCR buffers and deoxynucleotides, and specific probes.

10

15

20

25

MCA. The MCA technique is a method that can be used to screen for altered methylation patterns in genomic DNA, and to isolate specific sequences associated with these changes (Toyota et al., Cancer Res. 59:2307-12, 1999). Briefly, restriction enzymes with different sensitivities to cytosine methylation in their recognition sites are used to digest genomic DNAs from primary tumors, cell lines, and normal tissues prior to arbitrarily primed PCR amplification. Fragments that show differential methylation are cloned and sequenced after resolving the PCR products on high-resolution polyacrylamide gels. The cloned fragments are then used as probes for Southern analysis to confirm differential methylation of these regions. Typical reagents (e.g., as might be found in a typical MCA -based kit) for MCA analysis may include, but are not limited to: PCR primers for arbitrary priming Genomic DNA; PCR buffers and nucleotides, restriction enzymes and appropriate buffers; gene-hybridization oligos or probes; control hybridization oligos or probes.

Kits for Detection of Methylated CpG-containing Nucleic Acid. The reagents required to perform one or more art-recognized methylation assays (including those identified above) are combined with primers or probes comprising the sequences of SEQ ID NOS:1-103, or portions thereof, to determine the methylation state of CpG-containing nucleic acids. For example, the MethyLight, Ms-SNuPE, MCA, COBRA, and MSP methylation assays could be used alone or in combination, along with primers or probes comprising the sequences of SEQ ID NOS:1-103, or portions thereof, to determine the methylation state of a CpG dinucleotide within a genomic sequence corresponding to SEQ ID NOS:1-103, or to CpG island sequences associated with sequences of SEQ ID NOS:1-103, where the CpG island sequence associated with the sequence of the particular SEQ ID NO is that contiguous sequence of genomic DNA that encompasses at least one nucleotide of the particular SEQ ID NO sequence, and satisfies the criteria of having both a frequency of CpG dinucleotides corresponding to an Observed/Expected Ratio >0.6, and a GC Content >0.5.

SEQUENCE LISTING

from the trees have been their trees their trees their

	5	<110> Markl, Isabel Tomigahara, Yoshitaka Liang, Gangning Fu, Hualin Jones, Peter	
	10	<120> Methylation Altered DNA Sequences as Markers Associated with H	Human
		<130> 47465-14	
	15	<160> 103	
	13	<170> PatentIn version 3.0	
	20	<210> 1 <211> 510 <212> DNA <213> Homo sapiens	
	25	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
True Let Lat Call Lat Rad	30	<400> 1 ttgcaagccc ccttngctct tcctttgncc tcgcctacat attcagggga tcgcaatctc	60
31 5 22 .		actegegaaa taatttnttt etgtaagagg aageegeett teeeetetee caeegeeaag	120
m Minn	35	gtaaaggctg ctaaagtagc tcttcttgga aggaaaaata ttttaaaaag cagctgggtt	180
		gctctccaca agaagatggc agttttggga aaacccatta tgtgtccaaa tgccggtttc	240
		cttttcttgt ttaacgcttt ttagagggca aaaatgacgc tcatgtgaag cccacaggct	300
1.2	40	cgagccaatg tcgctgggct aattatgagt ctgcttatcc cactcccaaa tatccgagac	360
*==		gactcactca naagacattt ttactcttcc aagaattgng aattcagaan cagcttcccc	420
	45	acattctaag agaaaaaaa acttgtttaa cgggcacgtt tttgattttt ttgccgctgg	480
		cgaccttaat taaaagccgg gagctncnna	510
	50	<210> 2 <211> 313 <212> DNA <213> Homo sapiens	
	55	<400> 2	60
	55	gcactettaa aacgeetete tgcagteeca ggteegeget eeccaagaac tggeeagate	120
		gegeeggget tggeecetga caactetgee tectecacet gttgegttta eteegtttag	120
	60	ttggctgtgc agtctctggc cccaggtgtg cttttaaaac tcgaggaacg cgggtgttgg	180
		actcattcgc agcctcttgc ctctggttcc cgtgatccca cggtggcgag cttccaggct	240

		cagcgagga	g atctgggttt	gaacattcat	ctcccatgtt	actcttttct	tgctcctcgc	300
	5	gtccccaag	c cga					313
	10	<210> 3 <211> 16 <212> DN <213> Ho						
		<400> 3 gcttagcaa	a tttccctttt	ttattgttgg	ttttgtctgt	tggctcttac	cccctttcct	60
	15	tttcctgct	t cccctgagtc	agcaatgctg	agcccagcga	agcacagggg	gccaaaggga	120
		gagacacac	g gagcgccccg	gggtccccca	gcctcggcgg	ccaaa		165
	20	<210> 4 <211> 60 <212> DN <213> Ho						
	25	<400> 4 ggggggagt	c gtgcgtgtca	gatttaggcc	aggaagcgga	agtcgccagc	agcgagagtt	60
		taacctctg	t gggcgcagag	ggttgcgggg	attcagcgcc	cgggaccgtg	gatctgtgca	120
	30	gggagtcat	a ggtgtgtgtg	acatcagtgg	tggaacattt	tggctcgttt	tcacaattca	180
		gtcattatc	c tttctgcttt	cctcctggaa	gcattaaggt	tgaagttttc	ttctaaagat	240
,	35	caaagtttt	g atttgttata	ttagttcgga	tttgtttgat	ttttgtttgt	gttcggtttc	300
ğ. 2	55	aagtgctga	t ttgtaacttt	tctcccccc	cacacacacg	ccttttgacc	cctgaattat	360
Thin Hall		ttaaaagtc	c attgttggag	tggcaaacat	cctccgagac	tcaaagggca	aggccatggg	420
	40	cgctttatt	c cggctgctgc	tccaggaacg	tgggaaagca	gcggagtttt	attctagggg	480
		aaggaaaca	a aggcggccga	gtgccagctg	cacgtttggt	gggatttggt	catcaggggt	540
	45	ggacatgct	g cccaatggag	ctgtcggcag	tttgacccag	cttggtccgt	cgcgtcccga	600
	43	a						601
	50	<210> 5 <211> 80 <212> DN <213> Hor						
	55	<222> ()	sc_feature () " refers to a	an undetermi	ned base			
	60	<400> 5 gagtacgcgg	g ggcagaacca	gcgcaataca	gcattctggt	aggggaacta	attttgacta	60

		aaatatttgc	caattctaat	ccccaattcc	tggacctccg	ggtagctggc	aaggtatttt	120
	5	atgttagatg	tgtctggagt	aaggtgcacc	ggagtatttc	gacaagagac	tcaattcaat	180
	3	gcgtattaaa	acttgattga	gagagggaga	gagagaggtc	attttataaa	gaaagacctg	240
		tgaacactgt	agattggaaa	tttatgtttg	caaaataaaa	ggatgggttt	atcaagtgga	300
	10	tgcatttaca	aaatgtggca	tccaggtttc	gtaaaattag	ctgaattcta	cgggtaagat	360
		tatgaatgtg	gctcataaat	aattaatagg	tagtgaaaaa	gaatgtattt	tgcattaggc	420
	15	agtgcattca	atagtatttc	ggaaatgagc	acttcgattt	cctcggnttc	catgcgnggc	480
	13	cacctctcca	gagcagggca	ggcacccagg	gnggtgccca	cacaaacaag	cgcgtgtggg	540
		cattttcttg	gctcgtgcgc	tgaagtgcac	gctgggcctt	ggtgcccgca	ccctcagcct	600
	20	gggagatagg	gaggtggtgc	tacctgcagg	ccgattgtgt	ccccgccata	ggacactagt	660
		gggcggcaaa	cctcacaaga	ctcttgcagc	cagccttcag	cagagccagc	aaacccagcc	720
	25	gccaccgagg	gaggactgct	ccatgcagat	ggtcaggggc	tttcttctga	agacgcctcc	780
MALE MALE	23	cccacgatct	ctcaagttca	С				801
Mine if it the dust had not	30	<210> 6 <211> 204 <212> DNA <213> Homo	o sapiens					
ij	35	<400> 6 ccqqttqctq	ctggaggatg	ggactacgaa	qqatqqqqac	tecacteaac	caccqctcct	60
110			taatctcggt					120
Marie Henry Princes Miscelle			tactgctaga					180
	40	cccctccagc	tectecegeg	gcaa				204
	45	<210> 7 <211> 205 <212> DNA <213> Homo	o sapiens					
	50	<400> 7	aggagatasa	tassatasat				50
	50		cgggcgtgag					60
			gagatggttc					120
	55		acceggate		egettetace	LECGGAACGC	racateteda	180
		accectiga	acccgcacgt	cycaa				205
	60	<210> 8 <211> 597						

		<210><211><212><213>	10 343 DNA Homo	o sapiens					
	5	<400>	10						
			_	accagtacct	gggaccgggg	ggagcccggt	ccggccgcta	aaccgggctg	60
	10	gctggc	gcca	gggctccggg	aggtgcggtc	cggcggggaa	gccgtgatgg	gaagcgactc	120
	10	tgtcca	ggga	gtgtccttca	ccaccacact	cctcacgtcc	aggcagtgat	cgacggcctg	180
		gcggca	ccct	cacagcgggc	ccatagcacg	gggccacaca	cgtcccctga	gcttagcctg	240
	15	ggcaca	ttcg	tctgccgccg	agggcttaag	ccagtctgca	gcccgcgccc	cgtcactcgg	300
		acgcaa	gtcc	gtcgtccgct	ctgccacgcg	gccgctaagc	cga		343
	20	<210><211><211><212><213>	11 291 DNA Homo	o sapiens					
	25	<400> gtcctae	11 caca	ctccgcacac	aacgeggeeg	gtgttaagtc	tccaaacgcc	ccgagagctc	60
		caagga	ccgc	gcgcgcgaag	gcgccgtagc	aagtgggcac	acaccagaca	ccaccccggc	120
	30	gtgttc	cgcg	ggagaagcca	gtgcacacat	cctcccgcaa	ggcggggttg	ccagtgcaac	180
## ## ##		acagga	atcc	tgcccttttt	ctagaaaagc	cccctcccc	actttccctc	caatacactc	240
14	35	acctgc	gtct	caacagtttc	cttcttgcgc	tacacgcggc	cgctaagccg	a	291
Hall fleet from their the	40	<210><211><211><212><213>	12 266 DNA Homo	o sapiens					
		<400> gtccgga	12 atca	gtttccccgg	ccaggtcgct	tcccggtctc	aaccatttcg	cgctctgctc	60
	45	tgtccg	ctgg	tttgtccctg	cccggttcct	ctccccgggc	ctgtcagcct	ccgcttctct	120
		ggaggtt	cct	gggactcatc	tctgatccac	cgtcttgcgt	tctctgggcg	catcgacttc	180
	50	tctccat	cctt	cgggctcact	cctgactccc	tegetgeege	ccccgggggt	ttccacgcgt	240
		gtctcta	aacc	gcggccgcta	agccga				266
	55	<210> <211> <212> <213>	13 553 DNA Homo	sapiens					
	60	<220> <221> <222>	misc	_feature ()					

		<400> 13	
	5	gatcctggtc catcgaaacc ttgtgtgcat cggttagtgc ttcctgggcg tttgcttcta	60
		gccgacgctg acagtggagt gccagaaaga gggagaggac cgtcatggct actctgcccc	120
	10	tggtgtcacc atgcgctctc ccccggcacc ggcgaggcga	180
	10	gaggecete ggteagggea geageatece tgeaceetet eegeaggtgg teteceegae	240
		gccacaggtg gccagcaggg cgcgggtggg ggcaggagcg cctctcccct gcccaggcct	300
	15	cccgctcctt ctcggagcgc tgtggcgggg tggagagaca gccttctaca gctagtctag	360
		ctcggcgcgg ttcccgtctg tggcctccta atcccacagc cacagcgcct tcctctaacc	420
	20	tccctcggtg ggcttaaagc ctcccgttcc ttctgtctca ttccttctgc tccctcccc	480
	20	cgaaaccccc agatganagc tgggaacctg gcnccantna ctgagcnaac agtgttgacg	540
		ggccgnggcc caa	553
	25		
32. 32.		<210> 14	
		<211> 156	
Π.		<212> DNA <213> Homo sapiens	
	30	<213> Homo sapiens	
		<400> 14	
		gcgcacacag tgggtacaag gatgagctcg gtgtaaggaa tggaaagccc ccagtctaaa	60
J	35	ccaccgcccc ctagacacgg gtgaaaacct gcctaaaagc taactcaggc agtgactcta	120
: ==	55	tcacccgaag gggccctggg ccgcggccca agccga	156
	40	<210> 15	
: ====================================	40	<211> 300 <212> DNA	
: 🚅		<213> Homo sapiens	
	45	<220> <221> misc feature	
		<222> ()()	
		<223> "n" refers to an undetermined base	
	50	<400> 15	
	50	gttcacagcc cataaggtgg gggtggcccg aacctgaaac ggagcctgag ccaggatcct	60
			120
	<i></i>	gcaaccaaag totgaagege ceeceggtgg gggeegagag egetgeagge aggtggngge	120
	55	gcggggcagg cgggcgggcg aagggagctc cggntacgca ganaacgcgg agcgcccct	180
		teccacetge gegaggeat eetgeeeggg ggaggaaagg egggagteeg aggegggteg	240
	60	gattcccagc cagctccctc ctcacaggag gcggcccatt atccggcgtc gcaaagccga	300

<211> 322

	<212> DNA <213> Homo sapiens	
5	<400> 19 ccggcccgtc cctcttaata tggcctcagt tccgaaaacc acagaataga accgcggtcc	60
	tattccatta ttcctagctg aggtatccag gcggctcgga cctgctttga acactctaat	120
10	tttttcaaag taaacgcttc gggctgcagg acactcagct aagagcatca ggggggcgcc	180
10	aagaggcaag gggcggggat gggtggtggc tcgcctcgtg gcagaccgcc cgcccgctcc	240
	caagatccaa ctacgagctt tttaactgca gcaactttaa tatacgctat tggagctgga	300
15	attaccgcgg ccgctaagcc ga	322
20	<210> 20 <211> 255 <212> DNA <213> Homo sapiens	
25	<400> 20 taataagata ccaaatcggg cgagaaacga aaagctcctg gcctccgtat ttggggccag	60
	agacaccgca gggagtcagg tccccgccga caaatcggaa gaggcctgcg ggagttagcc	120
	agataatget etecetgtee taccegteee caccaatttg cettttacet geegeagage	180
30	ttgcttgaac caaaggggtt tgcggtcttc tcctcctcaa cttgcgatcc ccaggccttc	240
	gcgtcccgaa gccga	255
35	<210> 21 <211> 406 <212> DNA <213> Homo sapiens	
40	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
45	<400> 21	
	atgtgnnaag gctcgctntc catttctctt ttcctccttc tccctctctc atgtgcggtc	60
50	teceteaaca tecaaaceaa eegagtgegt etgaggtgaa ategtgeeag aettagagae	120
	ggctgccagg tttctctcaa gtcttggctt aacaaaagaa agcaaattac aaaaatggaa	180
	attttcaaac tagcgttcag tggtattcaa atcgacgttt gggtagcgca caggcacaga	240
55	ccgcattcgt gctattttgt gattaaaatg ataccaaaaa tacctccttg ctttggtttt	300
	cgtcttcgaa aacgacttct ttccttcttc taatttcccc cttacttttg ggagcggcaa	360
60	acccctgacc actctagaat tgctaacatt tggaccggcg tcgcaa	406

tion is the first first first first first first

Ş

South Waste Man Kreen South Box

	<210> 22 <211> 210 <212> DNA	
5	<213> Homo sapiens	
	<220>	
	<221> misc_feature <222> ()()	
10	<223> "n" refers to an undetermined base	
10		
	<400> 22	
	gcacgttcgn gcnncgtgta ccatnagctg ccaactggan gcaccnnggn aagggtgggg	60
15	gcctcctgga gacttngggg agagggatag ccggntaaag ctcctgtcct ttctataggc	120
	ataagcgggt ggtcaccacg gattggggat cccgaatccc tggctccaga tagacttaat	180
20	gaagaagcac ctggatccgg gccgcgncaa	210
	<210> 23 <211> 310	
25	<212> DNA <213> Homo sapiens	
i 1	<220> <221> misc_feature	
30	<222> ()()	
30	<223> "n" refers to an undetermined base	
	<400> 23	
<i>≟</i> 35	tcacgcttnc naaggctctg aatcctgagg gncagatctc caagaaggag ggaggctggt	60
	cctagttccc gaggtcctnn actaggtcta gatcactggg taaaagaagg ggagcggcan	120
me Green Stranff	cacgtatggg gtaggcgctc tcactactca catctcgaga cctttgccgg cgtagggctg	180
40	tccgggggga acgacccgcc ttttccggta tcggttgtca tggcggcgcc cagcccagcc	240
į	tggttttttc cggtagccaa ttgaactaac aaccccgttc cctttaggac taatctgtca	300
15	cgtcggcgca	310
45		
	<210> 24 <211> 304	
5 0	<212> DNA	
50	<213> Homo sapiens	
	<220> <221> misc feature	
	<221> misc_feature <222> ()()	
55	<223> "n" refers to an undetermined base	
	<400> 24	
60	ctctggtctg tgntggatac gcgtgttctt ctgcggagtt aaagggtcgg ggacgggggt	60
-	tctggactta ccanagcaat tccagccggt gggcgtttgg cagtcactta aggaggtagg	120

		gaaagcagcg agcttcaccg ggcgggctac gatgagtagc atgacgggca gcagcagcag	180
	5	ccagcaaaag ccctcgcaaa gtgtccagct gctgcactgc cgcggggact cccacagcac	240
		catgactagt tcgtgcgact ctgcancanc aaacggcttc cgaggaacac angatcgcgg	300
		gggca	304
	10	<210> 25 <211> 379 <212> DNA <213> Homo sapiens	
	15 20	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	25	<400> 25 aaaacncatn tgnagagene nteggeagag negeagetgg etgaeeeagg agaaggegeg	60
Harling Market		ctgggtgtgg ctgggacggc caaggccgcg gcttcccgcg tggggatgcg ctntggcgca	120
J.	30	aagctggtcc cggcggggcc aggcgtttgt gggcgggtga cggggatcta gggcttccgc	180
		tcgngattcc tcttgggctg tctttncggg tttggactcg cctgccaggc tgtgtgcagg	240
H den den den		gttcccgctg cctctggccg gcaggcgtcc gggctgcagg tgggccggca ggcaggtgtt	300
	35	agcgggaagg gagcacaggt agcgaggtgg gatcggcgac ctggctaggg tgtcggcaga	360
ii ha		atggaatgcg cggccgcta	379
And Left Bire have head	40	<210> 26 <211> 625 <212> DNA <213> Homo sapiens	
	45	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	50	<400> 26 gggacgcnag ccagggantt tgatccgttt tgaatgaaaa gaaagagaan ccaaaccaaa	60
		cctntcagtc atccaaaacc ttcaggcttc cagggaggtt ttgctataat tttctctaag	120
	55	catgactgtt tctgggggag gggaaagggg tggttgtatt tactgaaaat tcaaatcgaa	180
		ataataaatg gccaaatttg gacacttacg gacccaaaca gttttgctca cgccagagaa	240
		accgagagca cagggcttgc gtgaagccta tctcggcaga aggcaacatt ctaataaagc	300
	60	ccgtgggaaa acagattaca ttttcgccat gaataagtca tgcagtgaaa aatattgcct	360

		acagcctgtc gacttatatt attatcacgt ttttcaactc ggcgtgagga gggagaggag	420
		tgttcatatt tgactaggaa ttgcaggatc gatgcaaact ccagggcagc agccagactg	480
	5	gcatatgtgg ggctctccgg ttactttctc tgtatgtcgc gggtgagagg aacagcgagg	540
		acaatttagc gcaaacacac gaagggtcgg atctcaaggg ggcagcgctg ggagaaaggt	600
	10	tagggctgna gagcgnanag ncaaa	625
	15	<210> 27 <211> 499 <212> DNA <213> Homo sapiens	
	20	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	25	<400> 27 gneteenegt teeceteggg eggaaeggag geaaetttee ggagtetatt tttgttaaga	60
H H King lad tent and that that		caatcaactc caataactga gctgaagttt ttgtttaaaa agaaaaaaat ctgataagtg	120
		atgattttac ctacttgtgg acactagatt tcaattagga aggttttttt aaacggcttt	180
	30	ttgtaacttc gctgcaggaa gcaggtttgt ttctttttct tttctttta agagaaggtg	240
		tatttcactg gtgcaatggc ttggcacctc cggggcctgg gaggacctca gacctcccca	300
E.	35	gccctgggtt tctccgtctt caagaccaac taggaagggt caagcgggga gagggagtgg	360
ě.		agggtcaggt gagatetcag agetgeeeeg geeggeeeee gtetetttet aceteetett	420
die han dal		ccagagaacc agcggctcac accettetca acgcaggaca tgctcggcgg ccaaagccga	480
	40	attctgcaga tatccatca	499
	45	<210> 28 <211> 561 <212> DNA <213> Homo sapiens	
;	50	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
		<400> 28	
	55	gggcgattgt tattcaaacn ngntanctct ctgcggggnn gagnaatgng ggcctcgcac	60
		ggctncatcc ccgtcgagcn cagggcctcc ctgttctnct agacatncca aggagccaac	120
6	60	tcctccgcag aagttccccg cttctgctct tatttccaag cttcgcgctt tctacaaact	180
		ccctgttgcc ttgactttga tttccagccg tggtgagggt cagagtgaac cccggcgcgc	240

	tccccgacgg	catccccgca	caccaggata	ggagaaattg	gagggcctgg	gcctcggctc	300
5	ccgcagtcgt	cggaggaaga	acccaccgcg	gggtccccaa	gggaaagtga	agaggcccgg	360
J	gatttttcca	aagcgctgcc	aggaccccga	aggaaggga	ggagtcacct	gaagccgggg	420
	aagctccttg	ggtgctctcc	ttggatcctt	atgttcactg	actttcgcga	ngccccctgg	480
10	aggnggaaaa	teegegetgt	ttcccccaac	ttaacttcac	gcggccgcta	agccgaattc	540
	tgcngaaatc	attacactng	С				561
15	<210> 29 <211> 717 <212> DNA <213> Homo	o sapiens					
20	<222> ()	c_feature () refers to a	an undeterm	ined base			
25							
	<400> 29 actctccgcg	gtntcntggt	gcctcacagg	aggtggggct	ccctccaccc	ggtccccagg	60
30	cctctccctc	tgcccgagct	tcccggtcct	gcctccttcg	cctcgcctgc	ctgcccgact	120
30	ctgaaccctg	ctcctcttct	aactaaaagt	cagtgtttta	tttcctccgc	agtccaatgc	180
	ccgcgtttta	ccttattcaa	taagaagggc	ttcatttatg	gcaagacagg	acagccaggt	240
35	aataagggcc	tctgcacacg	cgggcccatt	ggaggggcgg	aactgcgaag	tcttcccgga	300
	agagcttcct	ggagagaagg	ggaacgagcc	agcgtttatt	gagcatctat	tatactaagc	360
40	atctgcttgg	cagttcacga	cggtcgcatt	ttttcatcct	tacagcgatc	cctattgtgt	420
	cgcttgcttt	aaagcctcac	agctcacaaa	gggctgggat	ttattccaga	tctctctc	480
	agatgccatc	tcacttccag	gtgtctctgc	tgctttgaac	gcgggaaacc	cacgcaaagg	540
45	agtgatttcc	aaggccttct	gtttggaata	tctttaatcc	tccccttatt	aactggaaaa	600
	actcccacgc	atccttcagg	gctcagctca	aatgtccttt	atntctgcag	ngaaactttc	660
50	ccaaggaaaa	ttagttacac	agctaatttt	agataaattg	agccagttga	tagaatt	717
55	<220>	sapiens feature					
60	<222> ()		n undetermi	ned base			

	<400> 30	
	tgatggatat ctgcagaatt cgggctttgn gacgccgggc acgcagtagg gaaaacagta	60
5	ttaaaacgcc ctacagaaaa tctcggcgaa gtccccggag aactctggtt tctaagatca	120
	gctgggcgca ctttctccgg gacgtccctt cttctcggtc tcagcgcctt cctgccctca	180
10	gccgcgccng tnttgttttg gtggcaaact gaaataagaa atggaaatat attggccttt	240
10	gctgctgcca gggatgagag gttgttgacg tcggcgcaaa	280
15	<210> 31 <211> 270 <212> DNA	
	<212> DNA <213> Homo sapiens	
20	<220> <221> misc_feature	
20	<222> ()()	
	<223> "n" refers to an undetermined base	
25	<400> 31 gnggnggna nrgggggatg gathtngga ganttnggtg atgatatat gaggattag	
	gnggnngnna nncggcgatg gatntnngna ganttnggtg atggatatct gcagaattcg	60
30	gcttagcggc cgcgaacaaa gagcgaacca aaggatgctt cgaattttta aaacggaatc	120
	tetgeaceca aatgeaggae tggtgaetta aggagetgeg aagtetgatt taeegggeet	180
	actetegace tgecececae ecceagetea gggggacett tttatentga acgeeagage	240
35	tacnnaccaa gtcgggtggc cacnnccaaa	270
	<210> 32	
40	<211> 347 <212> DNA	
	<213> Homo sapiens <220>	
	<221> misc_feature	
45	<222> ()() <223> "n" refers to an undetermined base	
	<400> 32	
50	tttggannta ngggggcgtg gcgtggatcc agtttccccc ggccaggtcn gcttcccggt	60
50	ctcaaccatt tegegetetg etetgteege tggtttgtee etgeeeggtt eeteteeeg	120
	ggcctgtcag cctccgcttc tctggaggtt cctgggactc atctctgatc caccgtcttg	180
55	cgttctctgg gcgcatcgac ttctctccat cttcgggctc actcctgact ccctcgctgc	240
	cgccccgggg gtttccacgc gtgtctctaa ccgcggccgc taagccgaat tctgcagata	300
60	tccatcacng aantctgcag anatncatcg ncgaannnca ccgcact	347

```
<210> 33
        <211> 342
        <212> DNA
        <213> Homo sapiens
    5
        <220>
        <221> misc feature
        <222>
              ()..()
        <223> "n" refers to an undetermined base
   10
        <400> 33
        gtagggcgcc gccgtgacag attagtccta aagggaacgg ggttgttagt tcaattggct
                                                                              60
   15
        accggaaaaa accaggctgg gctgggcgcc cgccatgaca accgataccg gaaaaggcgg
                                                                             120
        gtcgttcccc ccggacagcc ctacgccggc aaaggtctcg agatgtgagt agtgagagcg
                                                                             180
        cctaccccat acngtcggcc ggctcccctt cttttaccca gtgatctaga cctagtctag
                                                                             240
   20
        gacctcggga actaggacca gcctccctcc ttcttggaga tctgaccctc aggattcann
                                                                             300
        nnctttgctc acgagetcca accenaenca tecaaannne aa
                                                                             342
   25
        <210> 34
        <211> 370
        <212> DNA
        <213> Homo sapiens
30
        <220>
        <221>
              misc feature
        <222>
              ()..()
113
        <223> "n" refers to an undetermined base
   35
        <400> 34
        cattgtttac tttcgtctaa acgcggtgga agcccatgga agaaagcggt tagcagcaag
                                                                              60
  40
        gcagagccct gctccctctg cagccccagc tcccagcgcc ctggqctttc caqqcacctq
                                                                             120
        teegggtagg ggattgaggg cegtggeeag geeggeactt teetgetage egeagetgge
                                                                             180
        cacatgccca tctgaccctc cgagttctcc tctaaaaatg gggctgacag ccgctacctc
                                                                             240
   45
        acaaagtcca caccgggctc aacccgntgc cttcctcccc aacaggactc tgccaccctc
                                                                             300
        cctcaggatg cctgaggcc ccganctgca cctggccagc cantttgtga atgaggcctg
                                                                             360
   50
       nggggcgntt
                                                                             370
        <210>
              35
        <211> 213
  55
        <212> DNA
        <213> Homo sapiens
       <220>
        <221> misc_feature
  60
       <222>
              () ...()
              "n" refers to an undetermined base
```

1, 2

i.T

21 AUG

ž:

1.4

		<400> 35	
	5	aaaatacnan taaagegatg ettegaattt ttaaaaegga atetetgeae eeaaatgeag	60
		gactggtgac ttaaggagct gcgaagtctg atttaccggc ctactctcga cctgccccc	120
		acccccagct caggggacct tttgtctgaa cgccagagct actgaccagg tcggggggcc	180
	10	gcggcccaag ccgaattctg cagatatcca tca	213
	15	<210> 36 <211> 173 <212> DNA <213> Homo sapiens	
	20	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	25	<400> 36	
(3	25	gacnncgggt ttgtgtgtaa cagggtcagt ccccgtatct actttgcgaa agcttcgagg	60
1,1		cgagcgtgaa gtcaagggct gcggtggatg ggggtaaaan gcctcctcnt cccactgcct	120
The Real with State Control	30	gcnccgtctt ggggtaaccc ctanccccca cccggngttn cnctttaatg ctc	173
and the first H freeze	35	<210> 37 <211> 369 <212> DNA <213> Homo sapiens	
Hart Hall they have hard	40	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
i d	45	<400> 37 tcactgtgcc gggtctctcc tncccggtcc aactccctta cttgtcctca tctctgtccc	60
		caaggtccgt gacccgcgga ggtgatgggg gggataggag agccccaggg accgcagagg	120
		tgacacaatc gcccgcccgt cctccctcgc tgggagccga ttcagcctgt gccgagcctc	180
	50	tecettegeg tgeetetgeg caeageggtg geacegeagg acteegggte eeceegget	240
		ctccatcggg aagccggcaa atgcgcttcc tcagccagac cgcggcgggg tggggggggg	300
	55	gggggcggaa gttgaaatac tgggacagaa acacctgccc gtcccaaggg acggaaaact	360
		ggatgccaa	369
	60	<210> 38 <211> 123 <212> DNA	

		<213> Homo sapiens	
	5	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	10	<400> 38 gtcccttcgc cccgcttttn ctttccccna ggtcccagcg nccgaaccgg cggatgtcca	60
		cgaaacatag ggcgagccgg gggccangcg gggccgtgta aaatctcntg tggtcatttt	120
	15	gtg	123
	20	<210> 39 <211> 450 <212> DNA <213> Homo sapiens	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	25	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
	30	<400> 39 ctagccctgg aagagaatcc gaggctcagc cntgctgcag cacccaggac actgcatccc	60
		agcacctgcc cgaagatcag cccaggaccc aaaggaaagc aggctccaag ctccccggaa	120
		gccaaggaaa ataggaaaac atatcctgcc ccggggacac cttctggaac tatgaccaca	180
ii Li	35	tgcacttgac cttccggaac aatcaccgca tgcacctgac ctcccggaac tgtcaccacc	240
The state of the s		gegegeacet gaceteeegg caetgteacg acegegegea cetgacetee eggeactgte	300
1. L	40	atcaccgcgc gcacctcacc tcccggaact gtcaccaccg cgcgcacctg acctcccggc	360
	40	actgtcacga ccgcgcgcac ctgacctccc ggaactgtca tcaccaggcg cacctgaccc	420
		cccggcactg tcacgaccgc gcgcacctca	450
	45 50	<210> 40 <211> 593 <212> DNA <213> Homo sapiens	
		<400> 40	
		ggaccaagct gggtaaactg ccgacagctc cattgggcag catgtccacc cctgatgacc	60
	55		120
		acteegetge ttteecaegt teetggagea geageeggaa taaagegeee atggeettge	180
		cctttgagtc tcggaggatg tttgccactc caacaatgga cttttaaata attcaggggt	240
	60	caaaaggcgt gtgtgtgggg ggggagaaaa gttacaaatc agcacttgaa accgaacaca	300

		aacaaaaat	c aaacaaatco	gaactaatat	aacaaatcaa	aactttgatc	tttagaagaa	360
		aacttcaac	c ttaatgcttc	caggaggaaa	gcagaaagga	taatgactga	attgtgaaaa	420
	5	cgagccaaa	a tgttccacca	ctgatgtcac	acacacctat	gactccctgc	acagatccac	480
		ggtcccggg	c gctgaatccc	cgcaaccctc	tgcgcccaca	gaggttaaac	tctcgctgct	540
	10	ggcgacttc	c getteetgge	ctaaatctga	cacgcacgac	tccccccgcg	gca	593
	15	<210> 41 <211> 45 <212> DN <213> Ho	7					
		<400> 41 accaccaac	c aaatagggcc	tttcctgtta	acgaccacgc	ggcaaggggg	ccgggccctc	60
	20	gcacgcctc	g acggcctccc	ccactccaaa	gggactccga	tttcgcagga	tctcccgcct	120
		cccgcctct	g ctcccaacac	cctacgtttt	tctcttcctc	ctcatttacg	tatttacaat	180
	25	aaaacagcg	a agctgcacag	tctgtctcta	aatcaaacgc	ggttaccatc	aaagcctcag	240
But	20	actctatgt	c tcaaccgcaa	aaggtctgac	aggaaatcaa	ctcgggagtt	tgtcaattct	300
(n		ttaaactca	a agctctgtta	acgaaatctg	gatctttcct	cgctccccac	ctgcctcccc	360
	30	tgacaggag.	a atgactgtaa	aaggatcctg	tegteeeega	aagtcagcac	caagcacttc	420
H H H		acaaattgt	c aaatctcaaa	agcttacacg	cgcggca			457
in the true the the	35	<210> 42 <211> 21 <212> DNZ <213> Hor						
1: 22	40	<400> 42	t					
11 22			g aatgacgcgc					60
	45		g cttgggtgta					120
	73		gegeggteee			ctggtcgtca	ttctcgttgc	180
		taccegette	c cttgtccgac	acgreggege	a			211
	50	<210> 43 <211> 143 <212> DNA <213> Hon						
	55	<400> 43		~~~~~				
			c cgggggccca					60
	60		cagggggggt		ayaattcayc	cacciccag	calecctgtt	120
	50	uccccyayga	cgcgcctctc	a				141

	5	<210> 44 <211> 559 <212> DNA <213> Homo sapiens	
		<400> 44 acccactttc cattaacact aaataaaacg catccatgga tttcctctcc attccgaggc	60
	10	aacaggagtg catggcacat tgccctactc ccctgaagct cttcgctaac ctaagactcc	120
		agggtgagga agttagctgg agctttttaa agtgcatctc caaagagaat tttgctcaca	180
	15	ccatgagagc ccccaagaaa caccagggcc cccttagatg ccggagacca cgccctccag	240
	13	gaataagccg caccetetge ceageagate ettgegegag tagecetett teeetgggge	300
		taatcaagtg catgccacat gtcaccactc tcagctggca attcttcctc agaggcgcag	360
	20	actttcacgg aatccccagc aggggggtt aagagattca ggggaggccc cgcccgtgcc	420
		ttccacaaaa gtcgctttac cgtggctcgt gtcctgcggc cccaaggggg tagcctggga	480
	25	cgtgtattgg gagggcatag aggctccttc caggacaagc tgccagcctc cagtgggcaa	540
Hall Hall	20	ccatgtgaga ggcaaaatt	559
THE RESERVE OF THE PARTY OF THE	30	<210> 45 <211> 433 <212> DNA <213> Homo sapiens	
lle dism	35	<400> 45 gcgaacagca caaaggcttc attcctacga gagattaagt tttagagcaa atggacacga	60
		tcgttaaaga atttgatatt tccatgtaaa ctgcattagc aggttatgcg atccaaactc	120
Sad the hour had	40	acaggaacaa ctccaactct cggccatgcc ctatttcatg tctagatttg tttaaccgac	180
	40	ttacatcata atccaagaat acgaactaca gtatattctt acagcaaagt tattccttaa	240
•		aagcaaaacc gagccacctt tgaaaacacg cacacacatt atccacggca ctaaaacccc	300
	45	agtottgaco gagaaagaco aacaacttgg gggggaagaa aacaacttca gagccagago	360
		tcccaaagca gaaagcgctg gcggctgaag ggcacacgag gttccgctcc cgggcgaacg	420
	50	ggcggcgtcg caa	433
	55	<210> 46 <211> 487 <212> DNA <213> Homo sapiens	
		<400> 46 cccttagtat tccatgagcc accattttcc ccacgatccc tccagcctga acgatcacat	60
	60	cctactgtgg accacgactc tcccagcagc gggcgtttaa tatccagtta gcaggttctc	120

		accacccccc	egetggeteg	aatacagcat	etgeaeegag	ttcccgagaa	tcgtcaaccc	180
		agcaaatccc	ttaattggtg	gacatgaaaa	tccagggctt	tgtgctgtaa	taacagagtc	240
	5	ctgggggcct	ggggagtttg	tgccgcttgg	agctcaggtt	tctgggacag	aggctgagcg	300
		cagggcaggg	aggcaggtct	cacctggcac	ctcccagagt	cctcgccgag	cagatggaag	360
	10	cagaggctct	cgcgcccggc	ccccgccggg	agacctctct	ctctttccct	cggcctgctc	420
	10	tgccctctcc	cgccttctcc	ctgtctgatc	cttctctgct	gtcatgttct	ttgtcctcgc	480
		gccccga						487
	15	<210> 47						
	20	<211> 403 <212> DNA	o sapiens					
		<400> 47 gtcatataag	cacaaccatt	cccagggcca	ccctggatgc	atcagatcag	tcccccact	60
	25	ggtgaccaca	atggctggct	cagagtgcct	ttgaacagac	aggagaaaca	gacttcttgg	120
E King	25	agggagggac	cttcccacag	ggaatggcca	aggagctagg	tcttcagggc	ttgcatggcg	180
		tggagtgtgt	gctcaggtgc	acagtgaagc	aaacctgagg	ggacttgggc	cctgcgtcct	240
12	30	ccagcacaca	cgcacccttt	cgccgtcaca	tccggggcac	ccacccgtgg	aatatgtgag	300
		ccgcacttgg	ccagccacga	gttccagggc	caggaagtcg	tgcttctcgt	tcaggcgccc	360
	35	gttgtagaag	agcagcccgc	tctgctgcac	tgtcgcgtcc	cga		403
Mary Hard	40	<210> 48 <211> 155 <212> DNA <213> Homo	o sapiens					
		<400> 48						
		ggcgtggaga	ggaggggca	gaaactcagc	cgcccctacg	tttgctaaac	tgcgtccgcc	60
	45	agggggcgta	tttttctaaa	acgcacaaga	cgtttcgtgg	gttatcgatg	gtctcttgag	120
		cctccttgac	tgatggggat	tgaccgggcg	ggata			155
	50	<210> 49 <211> 256 <212> DNA <213> Homo	o sapiens					
	55	<400> 49	ttttctttaa	ataasaasa	2201001000	2+4242444	220021000	60
			aggtggagag					120
	60		aggtggacag gtggtttggg					120
			2-22-66333	Julyacaa	ggccagaggc	ayyayıllal	gatytayaya	180

		tgacaca	gtg	cccctccgcg	tgtgagtcca	cgaaggtcac	tactgaggct	ttgtgcttgt	240
		aaaaggc	cgc	cccgca					256
	5	<211> <212>	50 224 DNA	o sapiens					
	10	<400>	50		ggcgggagct	gttcgctggc	cggcctcact	ggagtaggaa	60
	15	ttttaga	tga	aactgagtcc	gtttctcctt	gaaggcaggc	agtattctta	gatctactat	120
	13	tcattta	aaa	agaaggaaaa	gaaaaaaaaa	tgactgctac	ttactgagaa	gaaaatttct	180
		gttctcc	tcc	gattccgctg	atcccgcttt	atccgcgcac	ctca		224
⊘: 1000g	2025	<211> <212>	51 313 DNA Homo	o sapiens					
Und Trail Und And			51 gga	cggcccaggc	cgcggcttcc	cgcgtgggga	tgcgctgtgg	cgcagagctg	60
Hard Hard		gtcccgg	cgg	ggccaggcgt	ttgtgggcgg	gtgacgggga	tctagggctt	ccgctcgtga	120
m III		ttcctct	tgg	gctgtctttc	cgggtttgga	ctcgcctgcc	cggctgtgtg	cagggttccc	180
: EE		gctgcct	ctg	gccggcaggc	gtccgggctg	caggtgggcc	ggcaggcagg	tgttagcggg	240
1	35	aagggag	cac	aggtagcgag	gtgggatcgg	cgacctggct	agggtgtcgg	cagaatggaa	300
Mar. Mars. Aug.		tgcgcgg	ccg	cta					313
	40	<211> <212>	52 385 DNA Homo	sapiens					
	45		52	2++a2++a+a	aagaaaaaa	aggggt ggg	agatagaaga	+aaa+aaa+a	CO
						agccggtcgc		_	60
	50					gcccacctgc			120
	50					gcaggcgagt			180
						ccccgtcacc			240
	55					cccacgcgg			300
						gtcagccagc	tgcggctctg	ccgaagcgct	360
	60	cctccgc	tcc	tttctcgcgc	cccga				385

<210> 53

		<211> <212> <213>	DNA Homo	o sapiens					
	5	<400>	53 gctc	ggttcggcaa	ggttcaggga	gacaaggtag	agaaggctgg	ggtgagcaag	60
		aagtcg	ggcg	gccgatcgtc	agggccacga	gcctcgcctt	gccttcttgg	aatcccaccc	120
	10	aacttt	aaag	gcccaaagat	cctgaaaatt	ccgaaagcga	aactgcgggc	tggtctccag	180
		aagttt	gaga	acggtctccc	aggctttcca	gcgtcgtccc	gggattctcg	gacaccacaa	240
	15	acgcca	tcaa	ccacgagcac	cggtgtccgt	ggctattgcc	ccgaatggtc	cccatccgcg	300
	13	tcccct	a						307
	20	<210><211><211><212><213>	54 182 DNA Homo	o sapiens					
§: =	25	<400>	54 cgaa	gccgtttgga	gggaacagcg	gtttccaagt	tcctgctgac	ttgagaagcc	60
		tctgcg	ggtt	tccgaatctc	cggcgcactc	ctgggcgcgc	tgcgggagct	gtagctcagc	120
LĪ	20	cagcca	ggga	gtagcggctt	tcatccgccg	ggaggagtct	ttcgagttca	atcgcggggg	180
The state of the s	30	ca							182
dress from hard to the fire	35	<210><211><211><212><213>	55 523 DNA Homo	o sapiens					
, <u></u>	40	<400> tcgggt	55 ttga	tccgccccaa	ccaaataggg	cctttcctgt	taacgaccac	gcggcaaggg	60
		ggccgg	gccc	tcgcacgcct	cgacggcctc	ccccactcca	aagggactcc	gatttcgcag	120
	45	gatctc	ccgc	ctcccgcctc	tgctcccaac	accctacgtt	tttctcttcc	tcctcattta	180
	15	cgtatt	taca	ataaaacagc	gaagctgcac	agtctgtctc	taaatcaaac	gcggttacca	240
		tcaaag	cctc	agactctatg	tctcaaccgc	aaaaggtctg	acaggaaatc	aactcgggag	300
	50	tttgtc	aatt	ctttaaactc	aaagctctgt	taacgaaatc	tggatccttc	ctcgctcccc	360
		acctgc	ctcc	cctgacagga	gaatgactgt	aaaaggatcc	tgtcgtcccc	gaaagtcagc	420
	55						cgcgcgggca	ctccggaaag	480
		gctgtgg	ggga	ccacccaaag	caccccctc	cacaccgcgg	gca		523
	60	<210> <211>	56 795						

<212> DNA

5	<210> 58 <211> 611 <212> DNA <213> Homo sapiens	
J	<400> 58 getteeceet teetteete egegetgeee eettgagate egaceetteg tgtgtttgeg	60
10	ctaaattgtc ctcgctgttc ctctcacccg cgacatacag agaaagtaac cggagagccc	120
10	tacatatgcc agtctggctg ctgccctgga gtttgcatcg atcctgcaat tcctagtcaa	180
	atatgaacac tcctctccct cctcacgccg agttgaaaaa cgtgataata atataagtcg	240
15	acaggctgta ggcaatattt ttcactgcat gacttattca tggcgaaaat gtaaactgtt	300
	ttcccacggg ctttattaga atgttgcctt ctgccgagat aggcttcacg caagccctgt	360
20	gctctcagtt tctctggcgt gagcaaaact gtttgggtcc ataagtgtcc acatttggcc	420
20	atttattatt tcgatttgaa ttttcagtaa atacaaccac ccctttcccc tcccccagaa	480
	acagtcatgc ttagagaaaa ttatagcaaa acctccctgg aagcctgaag gttttggatg	540
25	actgagaggt ttggtttggt ttctctttct tttcattcaa aacggatcaa actccctggc	600
	tcgcgtcccc a	611
30	<210> 59 <211> 291 <212> DNA <213> Homo sapiens	
35	<400> 59	60
	gagtttggca ggccccggat tccacaaagg agtaggcgcg gccagccgcc tccagccctg agctcagtaa attcggtgtc ctgaatgctc ccttcctgtc cttaccactg cgagctctct	120
40	tgggacaget ttetaggtte cactgegace tacttteege tecetgagtg ettetttget	180
10	gaaactgcag gcgaaaagat ctctttccca gaccgcagcg cactttgaga aggggctcaa	240
45	agtcgcccgc tctgaatccg gcaccggcaa ataggagtag ccgcatgcgc a	291
50	<210> 60 <211> 226 <212> DNA <213> Homo sapiens	
	<400> 60 gaaaacagat aaaacgccct acagaaaatc tcggcgaagt cccggaggac tctggtttct	60
55	aagatcagct gggcgcactt tctccgggac gtcccttctt ctcggtctca gcgccttcct	120
	gccctcagcc gcgcgcagct ttgttttggt gacaaactga aataagaaat ggaaatatat	180
	tggcctttgc tgctgccagg gatgagaggt tgttgacgtc ggcgca	226
60		

1,1

	5	<210><211><212><212><213>	61 580 DNA Homo	sapiens					
	,	<400> ctgtgat	61 tgca	ctcggcggat	ctcggtggca	gctgcctcct	tcatctccag	tgacgcctgc	60
1	0	atgctgt	tcct	aggcagtgtg	aggagtgaag	atgagatttg	gcgcatcttt	caacggagtc	120
1	0	tgagcaa	aagc	taaagggctc	cgattcgtgc	aagccaaggg	ctgcccctcc	tatcctgtcc	180
		tccttga	agga	cctgtgctaa	ggctttctca	tccaccaggc	caccatgggc	tgcgttcaca	240
1	5	aggaat	gctc	cctgtctcat	ctgctttata	gtaaagtcat	tgacgaggtg	gtggttatgt	300
		tcattga	agat	tgctgtgcaa	cgagacacag	tcactctgat	acagcaaacc	ctgcagggtg	360
2	Λ	tatcag	ggtc	ccctctgcat	gccctgggac	ctctctatct	tgtcctacaa	gtaggggtca	420
2	.0	taaaata	acga	cgctgaatcc	aaaggccttg	gctcaaactg	caaccgcctg	cctcatgcaa	480
		ccgaag	ccca	tgaggcctag	cgtcttccac	gaatgagggc	cactcccatg	gccacctcga	540
_ 2	5	gaatct	gctc	cacgctctga	acccgcgcac	ctcaagccga			580
2 2 mg 1500 1500 1500 1500 1500 1500 1500 150	0	<210><211><211><212><213>	62 633 DNA Homo	o sapiens					
<u>.</u>	~	<400> gcccagg	62 gaga	agccctccac	ggtgggcgtc	ctcctagaca	accagcaccc	cctgcaggca	60
. 3	5	ccctcgt	tctg	gcagaatcag	ccctttccca	cctgcaggcc	cttctcagcg	cctctgactt	120
an Shin P		cccacao	caca	gcacaggtta	caaactggtc	cctggcagtg	cactctagcg	ggcctctctc	180
1 4	0	acaagti	tctg	cgggcctcgt	ttcatggaaa	gcgggttgtg	gattcctgct	gcccttggat	240
		ggcccct	tgcg	cacgcacacc	tctgagcggg	cactgagcga	gcgtggggag	ctgctccctg	300
4	5	ggaacta	aggc	aggagctttt	aaacaccctt	acacacagcc	attctgcggg	aatacatgct	360
4	.)	ttcccg	gtaa	ggcttttact	gttcattcca	ggtaaattgg	aagtcgcaca	ccccaagctc	420
		caaata	caac	tcgttagctg	gcaggtctct	gaagccaatt	ccttctgagg	aaaatggaga	480
5	0	taatago	cagc	taccctccca	ggtgactggg	ggagaataaa	gtggctgtgc	atagtggtgt	540
		ttgcago	ctgg	tggctgctat	tatccttcat	tacagcttgt	aaaaagggtg	tctaggccat	600
5	5	ttacaca	acag	ataggccggg	tggggtaagc	cga			633
6	0	<210><211><212><212><213>	63 703 DNA Homo	sapiens					

, <u>.</u>

300

aggtgeggge ategggeaga geageteeag eaggeaggae etggggeete eaccetgeae

	ccctgtgccc cgcgtgtggc ggaaccgccc cgaggggagg ctgtcaccac g	ggtgacagge	360
	agccccacgc gagcctgaga accctcagcc cacctttttc tgtaatcaca	gcaggcatct	420
5	ctccggcaag tcaatccagt tccagctggt gctgcctccc ttgcctcatg	ggctttattt	480
	tagaactctg agcaataata aaaaagacgc tacccgctac aatagatgtg	gcagagaatc	540
10	tggctcttca cttcatcana gatcaccctg aaatgatggt tgttgttaa		589
15	<210> 70 <211> 748 <212> DNA <213> Homo sapiens		
20	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base		
	<400> 70 gctacatctn ctctacattc taactaacac ttgttatttt ctgtttttgt	ttatttattt	60
25	ttaatagcca ttctagtagg catgaagtgg tgtttgcctg ctttttttga		120
	ggaatagggt ggaattggtc cttaaccatc aattaagctg ggggccttag		180
30	attggctgtg acaatagcta aaggaggctg ctacctcata ctgaagagat		240
	tttgtcaccg gagagggcac cgaaccaact tattgtcttg gagggaagaa	_	300
	agaagacttg aacttctcag agaaaaaaac agtctacaga cttcatttta		360
35	acacactact gaaageteta eeetggggae etggettgae ttetaaceta	cncctgtgtt	420
	atttaggaag ageteecage tgetetgagt eteagtetee eaateagtga	aatggaggca	480
40	atagcacctg cctggctgca tcgccccaca gtgctgcaat gagcatccaa	cgagagaaag	540
	cttgtcacct gtgttgcaaa ctaagttaca caaatgcagg cagtagcagc	tagaagaaaa	600
45	tggttgggaa tctgaaaaga attaaagccc cccatgaatt tcttctcacg	cctcctccaa	660
73	aagccaggga ctgcttcacc ccgcctccag gactgctcgc tccagcattt	ccggcagctg	720
	ctgacagaat gtatgttgcg gctgtccc		748
50	<210> 71 <211> 599 <212> DNA <213> Homo sapiens		
5560	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base		

Hirto I II Herri Lark Hook with half death

		gctttttccg ttttgtctag a	aaatttgggt	tgcactaaat	tctcagctga	atgaagatga	180
		gaaggggctg gcagaggggg	tggctccagc	tctctgagaa	cctggctcct	tcccgggtgg	240
	5	cagggagaga tggcccctgg	ggagacgggg	agggtgcact	gcctcatgcc	caaaccacca	300
		gcttctagtt gagaaatcag	aattttctct	gcagaataag	gaaaaagcat	tgtcaccatg	360
	10	attcacgtgg agctggccac	actcaggaaa	ttcaatgggg	tcccacaggg	gctccgaggg	420
	10	ggaaggagag ggcctgggac	atgcccctcc	agccatcatg	gaacaggatg	ggcagggccg	480
		gccctcactg ctctctaaca	gtgaaaagcc	acatctccac	tttggaaaac	acaggcatgt	540
	15	gagageetgg gg					552
	20	<210> 74 <211> 450 <212> DNA <213> Homo sapiens					
And the will will that	25	<220> <221> misc_feature <222> ()() <223> "n" refers to a:	n undetermi	ned base			
ALL THE RULE	30	<400> 74 tggaggcttc gagggaagtg	aggttccctc	ggacacccta	gtgggaaggc	tccacgcggt	60
		aatggaacca cgctgtgaaa	cctttgcctt	tgggtgtcat	ggtggaagca	aatcttagaa	120
¥1	35	gacatttaat ttaaaaaatt	cagttttaaa	aaatgttgac	ttaaaaagca	gttttgaaaa	180
The first seem		acaacctgga attagcctga	gatcgatgcc	aactcttagc	agtctgtata	ctaaacacag	240
		ttaaacaact gtagctgctg	gcaagctgga	acctttttgt	aaagaagcac	ataaaaagga	300
#"H #"H	40	cagaactggt ggaaggtgca	ctggtctttc	cacatcgcca	ccaggcgttt	tgaagcgtgc	360
		tgctgacacg ctactcanat	gcttctggaa	gccaaacaat	aanaaaaanc	cccattgttt	420
	45	cccttgctgg gttttacccn	ccatggtgga				450
	50	<210> 75 <211> 432 <212> DNA <213> Homo sapiens					
	55	<220> <221> misc_feature <222> ()() <223> "n" refers to as	n undetermi	ned base			
	60	<400> 75 ggacaatgag gagggggtgc	acgtggaatc	cccacggata	ggccggacgc	cgggcaggag	60
	30	cetttagaga gatagagaga	ataatataa	agggetagta	actacctact	acctactace	120

THE PART HAS

1.1

accegataac ggeteecaag geecegtgtt tacattettt eecaetggaa geagaaatta

		tcacgccca	a attcctacct	gccttccctg	gattcctggt	ttcctaagaa	acgggtttgg	300
	5	cccacccct	g ggcgttcgaa	cagtccacag	aagcgggcaa	aggaaagacg	actcagtctt	360
	,	tecectecg	gc caatctcttc	tccgggacca	caaatcccag	aagtcaccgc	ggccgctaag	420
		ccga						424
	10	<210> 80 <211> 28 <212> DN <213> Ho	35					
	1520	<222> ()	.sc_feature () n" refers to	an undeterm:	ined base			
		<400> 80) gg gcanaggcga	tcaaaantgg	ggtgcgctgt	ggtgggcgac	acgtgtggcg	60
	25	cgggtctca	at tatccgccct	tttcacttcc	tggactggaa	atggcagacc	atatgatggc	120
		aatgaacca	ac gggcgcttcc	ccgacggcac	caatgggctg	caccatcacc	ctgcccaccg	180
	30	catgggcat	g gggcagttcc	cgagccccca	tcaccaccag	cagcagcagc	cccagcacgc	240
2 M M M M M M M M M M M M M M M M M M M	30	cttcaacgo	c ctaatgggcg	agcacataca	ctacggcgcg	ggcaa		285
Min Kin Last the the Kin I	35	<210> 81 <211> 40 <212> DN <213> Ho)1					
(3	40	<400> 81 cagatatgt	l ca tectectett	tccaaccctg	cgtccctttg	aggcctggtc	ggcgttccca	60
		acctgcccc	ct accccaccaa	cccctgtccc	tttggccatt	agtcccggat	tatctagcga	120
	45	tgccccgtg	gt accgtctggc	tttgctgttt	actccgcgct	cggccagttg	aggccttttg	180
	10	tatttatto	cc tgattttctc	ataggggtaa	agtgccttcg	ggaggatagg	acaagtccca	240
		tcctgttca	at acgaattaca	gctcggactt	cgggcccttt	tacactgcct	tttgtatctg	300
	50	ttaacttgo	g ctaaaaacga	ttcggttctt	ttttttgagg	aagggggttg	gggggcggag	360
		actctgtcg	yc ccagtcctga	gggccgcggc	gcgcaagccg	a		401
	55	<210> 82 <211> 26 <212> DN <213> Ho	58					
	60	<400> 82	? ca caactgtgtc	tcttacccag	gcacatgcac	tatccctgat	cccggtgcat	60

()..()

"n" refers to an undetermined base

<222>

<223>

220

60

<210>

<211>

	<212> DNA <213> Homo sapiens	
5	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
10	<400> 89 attggcccgn caggcgggaa acangctgnn nttctctnac cgttntccag cactgcccag	60
	accaggaggc gcagggagag gaggggncag cggttccgng accgctcctc ccgctgtccc	120
15	tgctctccag cctntgcctc tgcaggagcc cgcgggantt gccccaggcc cctgtcccca	180
	cctgtggctc ccgtcctggt cgctcccggg gccgcggcaa	220
20	<210> 90 <211> 273 <212> DNA <213> Homo sapiens	
25	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
30	<400> 90 gnagggnggn ggtcgcggac gccggtgggc agttcttgtt cggtgatgtg ggttaaaaag	60
	gactgcagcg aggagccggg gcggcgctcg gagtaatcac cggcggcatc aaaaagcgcc	120
35	atcatggcat cgaggtcgcg gtctgcttgg gagccggtgg cgccgccgcg caaggcagat	180
	gcctgcaggc gcatatccag ctcggtagcg ctccatacct cccacaggat ttcttccaca	240
40	gaggettggg ettgtatage etgeegeece gea	273
45	<210> 91 <211> 361 <212> DNA <213> Homo sapiens	
50	<221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
55	<400> 91 acggcttctn tnctaagtga cacggtgtgt gaaattcggt tggggaggta gttctgtaaa	60
	ctgcgtctcc ccgccagcta aggaagttga gtgaagggag cgttgccgtc tgggaatcgt	120
60	agtecteaca aaggegtgag taggeggeaa ataaggattt gggtttagee ttggggatte	180

actcctgtca aagctgttag agaagctccc anaactcnta aagtaacaga aactacttgc

	ggcaacattt	gtaacttcca	cctggctcat	tatcttccac	tgttaccttg	tgttctagat	300
~	aagttataat	ttattctaca	tatcgttcag	aagtcttgtg	cctgttccat	attgtnagca	360
5	t						361
10	<210> 92 <211> 462						
	<212> DNA <213> Homo	sapiens					
	<400> 92	_					
15	gctgcccaca	ctggatggga	aggaccggcg	cctgcagcat	ctgccctcca	agccttcgta	60
	gctccctcct	tcctgcagga	taaactctaa	actccttagc	acaacgtggg	agccttctca	120
20	gagactgggt	ccaacccatc	tccagccgca	gcctcccctc	ctggccccac	tgccacaccc	180
20	ccgggcctcc	ggccacactg	agcctctccc	ggtttcccag	gatacaacac	tcgcccattc	240
	atagtgtggt	gccttttgca	cgtgctgttc	ctctgcttgg	ggatgctgtt	ggtctttctc	300
25	agccaggtga	agaggacgct	gaatgtcacc	tgcttgagta	tcaggaccgg	ggactgggcg	360
	ctggacctag	actcttggcc	ctggagagaa	gccctgcatg	gggccgcagc	ctgcccccgt	420
30	ccctgctcac	agaaaagctc	agccttgcag	ccgcgtggga	ga		462
30	010 00						
	<210> 93 <211> 591						
35	<212> DNA <213> Homo	o sapiens					
	<400> 93	t		ataggaaga	ttaataataa	tataaaaaa	60
40						tgtcggggaa	120
40						gagtccgaac	180
						ctcctctctc	
45						gccacggcca	240
						cagggggtca	300
						agggcccctc	360
50						cacactggtg	420
						agacggccat	480
55						gcaggttccc	540
	acactgcggg	gggagcagga	cagacacaca	tgctcttgca	cgcgcacctc	a.	591
	<210> 94						

<211> 279 <212> DNA

	<213> Homo sapiens	
5	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	
10	<400> 94 ttntgagttt tggcctgccc acagtctagc cctggacaga gaatccgagg ctcagccatg	60
	ctgcagcacc caggacactg catcccagca cctgcccgaa aatcagccca gggacccaaa	120
15	ggaaagcagg ctccaagctc cccggaagcc aaggaaaata ggaaaacata tcctgccccg	180
13	gggacacett etggaactat gaccacatge acttgacett eeggaacaat eacegeatge	240
	acctgacctc ccggaactgt caccaccgcg cgcacctca	279
20 25	<210> 95 <211> 351 <212> DNA <213> Homo sapiens	
	<400> 95 cctttattat tgttaaacgt cacccagaaa acccttaact cttagacagc ggctctcatt	60
	aagcaaaagg ggaggcacat gaagctccag gcagggccgg gagggaaccg tgaagccaaa	120
30	ggctctggga gcccccaggc acctgcgttt gcattttcat cctggaggag accaggcctc	180
	tggggctgct ccccggggtg cagagaggag gggtctttct tggtgtgtaa catactcatt	240
35	gattcagtca cctgaccttt gactccatgt attttgttga gtctggatgt gtggtgtgct	300
	ctgcccagca gctgggatcc acatgagcac agacatggtc cccccgcggc a	351
40	<210> 96 <211> 171 <212> DNA <213> Homo sapiens	
45	<400> 96 ttgagtgtcg cgtgaatacc taggggacac tcaggggaat gatggctccc ccgagaggta	60
	aagggtggaa agaaggggcc tcagcaggtt aggtcttgct gggtccttct gtagggcgtc	120
50	tgggagatag atccgtgggg ctcctagggt cgcccctacc cggcgcgggc a	173
55	<210> 97 <211> 743 <212> DNA <213> Homo sapiens	
60	<220> <221> misc_feature <222> ()() <223> "n" refers to an undetermined base	

	<400> 97						
5	<400> 97 cctccctggc	ccttgttccc	aaggagcttc	ccttgtccca	gcctcttcgc	cagtgacttc	60
,	tcactggacc a	attcctttac	aaggagcctg	ttttttgtgt	tttttttta	cacctttttt	120
	cttctatttc a	acagaaggaa	caccggacgt	ccctntgtga	tggcagcagc	catgctgcct	180
10	ntgtttccgc	tcaggggttc	tntgccacct	ccaattccac	ccagtctntt	ggcctcggct	240
	gggcttcggc	tecegeetnt	gngccaaaaa	ttgcaatgcc	cgcggtcagg	gcnctttgcg	300
15	gagtctcacc	gcctgcggag	gcttgattcc	ctcctcacag	gcagcagcgt	ttgatggccg	360
13	gtgacncccc	cctttccaag	cacatntntc	atggcccctg	aatgccactt	acagggcgtc	420
	cctccctgtg	ctaagtgctg	cctgganctt	tgggtgtggc	agcagcaaan	acctctaccc	480
20	ttgnggatgt	tcgtttcggg	gnggaaagac	anatancaaa	gttggtcgta	aactgtaaag	540
	tgtgctggga	ggaaactgag	gcagggaggg	cctggtgcca	ctggggagcn	ctgccccgac	600
25	cccatgtgct	tcccaggctc	ccttggagcc	acgtggatgg	cgacttcctg	accttggagg	660
23	ccgnggncct	cantcctcat	gctcgatggc	gtcanccccc	tcttggggaa	atccaancat	720
	tcctgacctg	aaaatgcacc	cnc				743
30 35	<210> 98 <211> 589 <212> DNA <213> Homo	sapiens					
33	<400> 98 ttgccgcgct	gataaaggaa	gcgtctagaa	ggtctcccca	gccttcatca	tctgagactt	60
40	ggctttcagc	cccaaagcac	taggccctgc	tgttaacctt	ccaccattaa	cctttggtgc	120
40	tcttcaatta	gcagcagcca	ggggtccttg	gcaggtatga	gaatttggaa	ggacagcccc	180
	agggcatggc	ccccggctgc	agcaaaagtt	ctaagtgttc	ttctgttgga	aggaagccca	240
45	ggagatattg	atcagctgca	ggtggggag	gccccagatc	ccacccttgc	ctgcctccag	300
	gagaaggttc	tccatgggcc	aaaatggagg	cagagtccca	ctttgcctgg	gcagctccct	360
50	gagcatggct	ccctgtggac	ggagctgagt	gacgtcatga	ctctaggcct	caacaaaaga	420
20	gctttggaaa	atcccgatga	ttcgaattgt	attaaatcaa	caaacatcgg	gttgcacagt	480
	tactagaaaa	cggagatctg	cgtcatcact	tactagacac	gtgaccttga	. acggcggctt	540
55	ccccgtgtga	aacagcaaag	ttctgtaacc	cccatgaacg	cgcctctca		589

<210> 99

<211> 538

60 <212> DNA

<213> Homo sapiens

<400> 99

	tgccgcgtct g	accctactc	tcacaaagac	tttccaacta	gcataattga	gttaaatggt	60
5	cccccaact c	ccttaattc	aagctaaact	tgcagtttaa	caactatagg	agtgatatct	120
	acacattaat g	ccacacttt	aacatgccta	acactacaca	tgaacacgct	tccgggtgct	180
10	gttacatccc g	ctctctccc	aagcacgaga	cacaggcagg	atgctgacgt	cctgcttctc	240
10	tgctgcgggc g	ıggaagtcaa	gactccggat	ttgctgcagg	agttgccgtg	gggatcctga	300
	cttcacgcag g	gagatggtcg	gcctctggaa	gtgcctggcc	cgtttatcct	tgaaatctac	360
15	ctgtgcaggt g	gtccttgcc	tcagcccctc	aggacaacac	aggtctttcc	taagttacag	420
	ggagaccatc a	ıgattgtcgt	gtccgagccc	cctgaagtgg	aacccacagt	ctccattcag	480
20	tctgccctca g	gtttccctcc	cctctgcagg	gccattgctg	ctgtggacgc	gcctctca	538
25	<210> 100 <211> 486 <212> DNA <213> Homo	sapiens					
	<400> 100 agaggtagaa a	aaaggagtta	gaagcaaaga	ggaaaaaata	aataaacagg	caacaaaaac	60
30	ccaacccagc c						120
	aacgctgggg a	agtggagtgg	gccccggcct	tggggactgc	agagcccgct	cagccctggg	180
	tggctgggcc (cacatgggct	gtgccccagg	agcacaggag	gacccagagg	gtggccgaga	240
35	gageetegee g	gggctccggt	atgggtcctg	gcccctcaca	ggtgcgagcc	tggcccagtg	300
	actgtggacg (ctgtgggaga	gcaggcctcc	gatacgcagg	gctgggactg	ctgacctgga	360
40	aggtggtgcc g	gggcgtgtct	ggtgaaggcg	ccgttggcag	ctagagagag	acggcggatg	420
	gggtgacgcc a	attacccacg	gtcccagttt	tgaggcttga	cggtgacgga	aaaggacgtc	480
45	ggcgca						486
50	<210> 101 <211> 450 <212> DNA <213> Homo	sapiens					
	<400> 101 aattgaacca (gggtgcacgg	ccagcgccag	acacagtgag	cttcatggca	actccagttt	60
55	accggtgaga a	accatggggc	cactcagaga	ggcaaagagc	ctcacccgag	tgagtcctct	120
	ggcttctccc	cacctgggcc	gggccccagg	ccgcgctgtg	gttccctttc	cagccgtcat	180
60	ccctgggtga 1	tgggaggtgg	gcattctgtt	caaccttgtg	ggtcagggag	ccagggccag	240
00	tgtgcagatg	agaagaggct	gcggttactg	gcgatgcgag	ggactgtccc	cttcgtgggc	300

		actiticiti itgaggedag tgaaatgigt teeciggggi igiatieeig agaaggeete	360
	5	atttaaaggg agccgccaaa ccaagtgggc ttagcaaaag cagtttgtca cctggcagca	420
	J	cgtgtgagcc tcgcccggac gcgcctctca	450
	10	<210> 102 <211> 292 <212> DNA <213> Homo sapiens	
	15	<400> 102 agcgcggcct ggcagattgc ccattaatga aactcagtgg gcagaggctg ctgagggaca	60
		cggattccca ctccccgggg gagggggtgg aaatggcttc ctccctctgc ttccctacca	120
	20	ccagtaatgg ggagctcacc atgcttagaa gactcttcct tgcatggagt tcgggcctcc	180
	20	tccctgcacc taccacccta gtggccccaa gtcttaaggc tgaaggttaa tcctgtgtcc	240
		ttcagaagca aaggctgcaa ccgataccaa acagaggtgg ccagcgcggg ca	292
force, at the first first fact that the	25	<210> 103 <211> 395 <212> DNA <213> Homo sapiens	
	30	<220> <221> misc_feature <222> ()()	
å	35	<223> "n" refers to an undetermined base	
STATE OF THE STATE		<400> 103 agagettate cegegageae aagggageeg gggeetggge egeegtggga aggggeteet	60
	40	gccttccggg gacgcggtca gggaagtcca gccggggtgc tctctgcact gcgggtgccg	120
		ggctcggcag aggccaaccc ggcaaaacga gcaggatctc ccggccccac cctagtgggc	180
	45	tccgcctgcc ccaacaacca tcctgccatc ctccctgcga gacaggtgac tttcctctct	240
		gatgcggtgc atctgtcatc tgtctaacgg gcccattccc cagtgaaaca cccccaacca	300
		aagacacgaa ggggaaggcg caagcttcta ccaagctcan tttgcccatc tggtgcccac	360
	50	ctgcctngta tttggtgact tggaggatag gaagg	395

25

30

35

We claim:

- 1. A diagnostic or prognostic assay for cancer, comprising:
- (a) obtaining a tissue sample from a test tissue;
- performing a methylation assay on DNA derived from the tissue sample, (b) wherein the methylation assay determines the methylation state of a CpG dinucleotide within 5 a DNA sequence of the DNA, and wherein the DNA sequence is a sequence selected from the group consisting of sequences of SEQ ID NOS:1-103, sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID 10 NOS:1-103, and combinations thereof, wherein the CpG island sequence associated with the sequence of the particular SEO ID NO is that contiguous sequence of genomic DNA that encompasses at least one nucleotide of the particular SEQ ID NO sequence, and satisfies the criteria of having both a frequency of CpG dinucleotides corresponding to an 15 Observed/Expected Ratio >0.6, and a GC Content >0.5; and
 - (c) determining a diagnosis or prognosis based, at least in part, upon the methylation state of the CpG dinucleotide within the DNA sequence.
 - 2. The diagnostic or prognostic assay of claim 1 wherein the DNA sequence is a sequence selected from the group consisting of CpG island sequences associated with sequences of SEQ ID NOS:1-103, CpG island sequences associated with sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103, and combinations thereof.
 - 3. The diagnostic or prognostic assay of claim 2 wherein the DNA sequence is a sequence selected from the group consisting of CpG island sequences associated with sequences of SEQ ID NOS: 2, 4, 6, 7, 9-16, 19, 20, 22-33, 35-43, 48, 51-55, 59, 60, 64, 71, 76, 78-81, 84 and 87-90, and combinations thereof.
 - 4. The diagnostic or prognostic assay of claim 1 wherein the methylation assay procedure is selected from the group consisting of MethyLight, MS-SNuPE, MSP MCA, COBRA, and combinations thereof.
 - 5. The diagnostic or prognostic assay of claim 1 wherein the methylation state of the CpG dinucleotide within the DNA sequence is that of hypermethylation, hypomethylation or normal methylation.
 - 6. The diagnostic or prognostic assay of claim 1 wherein the cancer is selected from the group consisting of bladder cancer, prostate cancer, colon cancer, lung cancer, renal cancer, leukemia, breast cancer, uterine cancer, astrocytoma, glioblastoma, and neuroblastoma.
 - 7. A kit useful for the detection of a methylated CpG-containing nucleic acid comprising a carrier means containing one or more containers comprising:

10

15

- (a) a container containing a probe or primer which hybridizes to any region of a sequence selected from the group consisting of SEQ ID NOS:1-103, and sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103; and
- (b) additional standard methylation assay reagents required to affect detection of methylated CpG-containing nucleic acid based, at least in part, on the probe or primer.
- 8. The kit of claim 7, wherein the additional standard methylation assay reagents are standard reagents for performing a methylation assay from the group consisting of MethyLight, MS-SNuPE, MSP MCA, COBRA, and combinations thereof.
- 9. The kit of claim 7, wherein the probe or primer comprises at least about 12 to 15 nucleotides of a sequence selected from the group consisting of SEQ ID NOS:1-103, and sequences having a nucleotide sequence at least 90% identical to sequences of SEQ ID NOS:1-103.
 - 10. An isolated nucleic acid molecule comprising a methylated or unmethylated polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:97, and SEQ ID NO:100.
 - 11. The nucleic acid of claim 10, wherein the nucleic acid is methylated.
 - 12. The nucleic acid of claim 10, wherein the nucleic acid is unmethylated.

Abstract

5

There is disclosed 103 novel methylation-altered DNA sequences ("marker sequences") that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.